



Market snapshot



Equities - India	Close	Chg .%	CYTD.%
Sensex	81,381	-0.3	12.7
Nifty-50	24,964	-0.1	14.9
Nifty-M 100	59,213	0.5	28.2
Equities-Global	Close	Chg.%	CYTD.%
S&P 500	5,815	0.6	21.9
Nasdaq	18,343	0.3	22.2
FTSE 100	8,254	0.2	6.7
DAX	19,374	0.8	15.7
Hang Seng	7,621	0.0	32.1
Nikkei 225	39,606	0.6	18.4
Commodities	Close	Chg .%	CYTD.%
Brent (US\$/Bbl)	80	1.0	3.2
Gold (\$/OZ)	2,657	1.0	28.8
Cu (US\$/MT)	9,650	0.7	14.0
Almn (US\$/MT)	2,614	1.5	11.4
Currency	Close	Chg .%	CYTD.%
USD/INR	84.1	0.1	1.0
USD/EUR	1.1	0.0	-0.9
USD/JPY	149.1	0.4	5.7
YIELD (%)	Close	1MChg	CYTD chg
10 Yrs G-Sec	6.8	0.01	-0.4
10 Yrs AAA Corp	7.2	0.01	-0.5
Flows (USD b)	11-Oct	MTD	CYTD
FIIs	-0.5	-6.72	4.8
DIIs	0.44	7.33	47.7
Volumes (INRb)	11-Oct	MTD*	YTD*
Cash	877	1204	1298
F&O	1,09,246	4,20,333	3,82,104

Note: Flows, MTD includes provisional numbers.



Today's top research idea

Federal Bank: Growth outlook steady; getting futureready under new leadership

- Federal Bank (FB) has demonstrated a strong growth trajectory over FY22-24, with 20% CAGR in its loan book and 18% deposit growth. Over FY25-27, we believe the bank is well poised to deliver an 18% loan CAGR, aided by effective risk management and fintech partnerships.
- ❖ The bank views fintech partnerships as vital for product distribution, tech integration and network expansion to boost customer acquisition in FY25, as it is optimistic about the lifting of regulatory restrictions on card issuance soon.
- ❖ In Jul'24, FB received the RBI's approval for Mr. KVS Manian as the new MD and CEO beginning Sep'24. With his extensive banking expertise, Mr. Manian is expected to drive strategic changes and drive next leg of growth and profitability for the bank after already delivering robust performance over the last few years.
- ❖ We estimate FB to achieve RoA/RoE of 1.3%/15.2% by FY27, making its current valuation at 1.2x FY26 BV attractive for long-term growth; thus, we maintain our BUY rating with a TP of INR230 (1.5x FY26E ABV).



Research covered

Key Highlights
Growth outlook steady; getting future-ready under new leadership
Lower growth, higher CoR drive earnings miss
Profitability to maintain as growth moderates
Equity AUM crosses ~INR33t – another crest amid volatilities
Individual WRP for private players grows 28% YoY in Sep'24
Acute therapies drag overall IPM growth for Sep'24
Aug'24 IIP down to a 22-month low


Chart of the Day: Federal Bank (Growth outlook steady)

Ш

Estimate healthy 18% loan CAGR over FY25-27E



Share of high-margin products (ex-MSME) rose to 7% in FY24 vs. 2.4% in FY22



Research Team (Gautam.Duggad@MotilalOswal.com)

^{*}Average



In the news today



Kindly click on textbox for the detailed news link

1

Reliance Industries in talks to acquire stake in Karan Johar's Dharma Productions

Reliance Industries in talks to acquire stake in Karan Johar's Dharma Productions

2

ONGC eyes small LNG plants to carry gas from far-off fields

ONGC plans to establish mini-LNG plants at five locations in Andhra Pradesh, Jharkhand, and Gujarat to liquefy natural gas from wells without pipeline connections.

3

Jio writes to minister for Satcom spectrum auction
Reliance Jio has urged
Communications Minister
Jyotiraditya Scindia to auction satellite spectrum and reissue the regulator's consultation paper to ensure fair competition between satellite and terrestrial networks.

4

Anti-dumping step: India may raise the bar to block entry of cheap steel

Stringent quality checks can stem the tide of imports as producers scour for markets amid sluggish demand and steep duties imposed by the US and the EU, which has increased risk of dumping into India.

5

Smaller cities drive premium phone sales in festive season

Steep discounts on Apple and Samsung smartphones boosted sales in smaller Indian towns and cities during this festive season, outperforming major metros.

6

QIP fundraising hits record high this year; 71 firms mobilise Rs 88,678 cr

The gains in the equity markets, powered by robust flows from foreign and domestic investors have helped stocks command higher valuations

7

SC's tax ruling may boost commercial realty investments

The Supreme Court's decision permitting input tax credits for construction used in taxable services is set to boost commercial real estate investments in India.



Federal Bank

 BSE SENSEX
 S&P CNX

 81,381
 24,964

FEDERAL BANK YOUR PERFECT BANKING PARTNER

Bloomberg	FB IN
Equity Shares (m)	2448
M.Cap.(INRb)/(USDb)	459.8 / 5.5
52-Week Range (INR)	207 / 137
1, 6, 12 Rel. Per (%)	2/8/2
12M Avg Val (INR M)	2386
Free float (%)	100.0


Financials & Valuation (INR b)

manerals & valuation (note 5)						
Y/E Mar	FY24	FY25E	FY26E			
NII	82.9	96.8	117.5			
OP	51.7	61.5	77.1			
NP	37.2	41.2	49.8			
NIM (%)	3.3	3.2	3.3			
EPS (INR)	16.3	16.9	20.5			
EPS Gr. (%)	14.5	3.5	20.9			
BV/Sh. (INR)	119	134	152			
ABV/Sh. (INR)	113	127	143			
Ratios						
ROE (%)	14.7	13.4	14.3			
ROA (%)	1.3	1.2	1.3			
Valuations						
P/E(X)	11.4	11.0	9.1			
P/BV (X)	1.6	1.4	1.2			

Shareholding pattern (%)

As On	Jun-24	Mar-24	Jun-23	
Promoter	0.0	0.0	0.0	
DII	44.7	44.9	41.8	
FII	29.4	29.3	27.1	
Others	25.9	25.8	31.1	
FII Includes depository receipts				

Stock performance (one-year)



CMP: INR187 TP: INR230 (+23%) Buy

Growth outlook steady; getting future-ready under new leadership

Rising mix of high-yielding products to boost margins

- Federal Bank (FB) has demonstrated a strong growth trajectory over FY22-24, with 20% CAGR in its loan book and 18% deposit growth. Over FY25-27, we believe the bank is well poised to deliver an 18% loan CAGR, aided by effective risk management and fintech partnerships.
- The bank views fintech partnerships as vital for product distribution, tech integration and network expansion to boost customer acquisition in FY25, as it is optimistic about the lifting of regulatory restrictions on card issuance soon.
- We reckon that the implementation of LCR draft guidelines in their current form will impact FB's LCR by ~1240bp. However in that scenario, if the bank were to raise required deposits to restore its LCR back to 110% than as per our calculations, FB's RoA and margins would be impacted by 3bp and 8bp, respectively. Please refer our note for more details here.
- In Jul'24, FB received the RBI's approval for Mr. KVS Manian as the new MD and CEO beginning Sep'24. With his extensive banking expertise, Mr. Manian is expected to drive strategic changes and drive next leg of growth and profitability for the bank after already delivering robust performance over the last few years.
- We estimate FB to achieve RoA/RoE of 1.3%/15.2% by FY27, making its current valuation at 1.2x FY26 BV attractive for long-term growth; thus, we maintain our BUY rating with a TP of INR230 (1.5x FY26E ABV).

Growth outlook steady; business mix shifting toward high-yielding products

FB achieved a robust 20% YoY credit growth in FY24, with 20% YoY growth in retail loans and significant growth in high-yield segments like credit cards (73% YoY) and microfinance loans (107% YoY). In commercial banking, the bank is enhancing its focus on supply chain growth and high-margin products, which now make up 24.8% of its total portfolio, up from 19.8% in FY22 (excluding business banking, the high-yielding book stands at ~7% vs. 5% in FY22). FB's cautious approach to unsecured loans, compared to larger peers, positions it well to boost the share of high-yield loans and margins. Accordingly, we estimate an 18% loan CAGR during FY25-27.

Robust deposit franchise; LCR ratio remains a concern

FB's deposit growth was aligned with credit growth and stood at 18% YoY in FY24, driven mainly by 24% YoY growth in term deposits. CASA deposits saw modest growth, accounting for ~30.1% of the mix in 2QFY25. Despite the RBI's embargo on its partnership with OneCard, FB's strong fintech collaborations remain vital for enhancing cross-selling opportunities and attracting strategic partners. With a CD ratio of ~83%, the bank is well-positioned for growth, although its LCR at 112.6% raises concerns, especially with potential RBI regulations that could reduce it by ~1240bp. As per our calculation, if the bank raises necessary deposits to achieve a 110% LCR, its RoA and margins would be affected by 3bp and 8bp, respectively.



Pace of NIM moderation to ease supported by high-yielding mix

FB's NIM contracted to 3.16% in 1QFY25, primarily due to rising funding costs linked to a soft CASA ratio, although the pace of contraction has been slowing. The bank's lower fixed-rate loan portfolio (at 29%) will further add to margin pressure as the interest rate cycle turns. The bank is focusing on increasing high-yielding loans to strengthen margins, which are ~120bp lower than larger peers' margins, while the difference in the cost of funds stands at ~60bp. Despite setbacks from the RBI's embargo on its OneCard partnership, FB's strong fintech collaborations are key to enhancing cross-selling opportunities and boosting profitability.

Cost ratios to improve gradually; estimate C/I ratio of 50% by FY27


Despite minimal branch additions between FY16 and FY22, FB faced high operational expenses due to significant investments in technology, compliance, and rising wage costs. However, from FY23 to 1QFY25, the bank added 146 branches, demonstrating its commitment to growth and digital infrastructure, resulting in a higher C/I ratio of 54.5% in FY24. With ongoing technology investments and branch expansion, the C/I ratio is expected to remain ~54% in FY25 before gradually declining to 50% by FY27.

Strong underwriting enables healthy asset quality; est. credit cost of 30-40bp


FB has maintained strong asset quality, with its GNPA/NNPA ratios improving to 2.1%/0.7% in FY24, driven by controlled slippages and robust recoveries. This success is attributed to strategic customer selection and strong underwriting practices, which remain effective even in co-lending partnerships. Under Mr. Srinivasan's leadership, the bank has enhanced its underwriting standards, leading to a gradual decline in gross slippages, particularly in corporate and SME segments, while maintaining a lower unsecured loan mix. With credit costs estimated to be around 30-40bp, we expect GNPA/NNPA ratios at 1.9%/0.6% by FY27.

Valuation and view

- FB posted a 20% CAGR in its loan book during FY22-24 and improved its RoA to ~1.3% in FY24 from 0.9% in FY22, despite NIM pressure and higher cost ratios.
- In Jul'24, FB received the RBI's approval for **Mr. Manian as the new MD and CEO** starting Sep'24. With his extensive banking expertise, Mr. Manian is expected to drive strategic changes and drive next leg of growth and profitability for the bank after already delivering robust performance over the last few years.
- We estimate FB to achieve RoA of 1.3% and RoE of 15.2% by FY27, driven by improved margins and a continued shift toward higher-yielding products. As revenue growth outpaces cost growth, we expect the C/I ratio to decrease to ~50% by FY27, down from 54.5% in FY24.
- With current valuations at 1.2x FY26 book value presenting an attractive long-term investment opportunity, FB is well-positioned to leverage its strong balance sheet and extensive customer base for sustainable profitability. Supported by new leadership's focus on growth, we maintain our BUY rating on the stock with a TP of INR230 (1.5x FY26E ABV).



Buy



Avenue Supermart



Estimate changes TP change Rating change

Bloomberg	DMART IN
Equity Shares (m)	651
M.Cap.(INRb)/(USDb)	2975.6 / 35.4
52-Week Range (INR)	5485 / 3619
1, 6, 12 Rel. Per (%)	-14/-14/-7
12M Avg Val (INR M)	2167

Financials & Valuations (INR b)

Tillalicials & Valuatio	indicials & valuations (into 5)						
Y/E March	FY24	FY25E	FY26E				
Sales	508	589	700				
EBITDA	41	47	59				
Adj. PAT	25	29	36				
EBITDA Margin (%)	8.1	8.0	8.4				
Adj. EPS (INR)	39	44	55				
EPS Gr. (%)	6	14	24				
BV/Sh. (INR)	287	332	387				
Ratios							
Net D:E	0.0	0.0	0.0				
RoE (%)	14.6	14.3	15.4				
RoCE (%)	14.3	14.1	15.2				
Payout (%)	0.0	0.0	0.0				
Valuations							
P/E (x)	117.3	103.1	82.8				
EV/EBITDA (x)	72.5	62.9	50.6				
EV/Sales (X)	5.9	5.1	4.3				
Div. Yield (%)	0.0	0.0	0.0				
FCF Yield (%)	0.0	-0.1	0.1				

Shareholding pattern (%)

		,	
As On	Jun-24	Mar-24	Jun-23
Promoter	74.7	74.7	74.7
DII	8.0	8.6	7.7
FII	9.2	8.3	8.2
Others	8.1	8.5	9.5

FII Includes depository receipts

Lower growth, higher CoR drive earnings miss

CMP: INR4,573

DMART reported weak results in 2QFY25 as consolidated revenue growth moderated to 14% YoY (from 19% YoY in 1Q) with modest EBITDA growth of 9% YoY (7% miss) due to the higher cost of retailing (CoR).

TP: INR5,300 (+16%)

- DMART management indicated that the impact of online grocery formats was clearly visible, especially on large metro DMart stores that operate at a very high turnover per store. DMart reported a moderation in like-for-like (LFL) growth for 2+ year old stores to 7.5% in 1HFY25, with a sharp moderation to ~5.5% in 2Q (vs. ~10% in FY24).
- An increase in the GM&A contribution (up ~25bp YoY) resulted in a 25bp improvement in gross margin (GM). However, EBITDA margins declined 40bp YoY on weaker store productivity (revenue/sqft flat YoY) and higher CoR (opex up 9% YoY on cost/sqft). As a result, EBITDA increased 9% YoY (7% miss) and PAT was up 6% YoY (11% miss).
- DMART added six stores in 2QFY25 (12 in 1HFY25). Accelerated store additions remain the biggest growth driver for DMART and we expect the pace of store additions to pick up in 2HFY25 (four added in Oct'24).
- We lower our FY25/FY26 revenue estimates by 2/4%, EBITDA estimates by 6/10% and EPS by 8%/14%, as weaker store productivity and higher CoR offset slightly higher store additions. We reiterate our BUY rating on the stock with a TP of INR5,300.

EBITDA misses estimates on lower productivity and higher CoR

- Standalone revenue grew 14% YoY to INR141b (in line), driven by 13% area additions, while revenue/sqft remained flat at INR36k (annualized).
- Consolidated revenue grew 14% YoY to INR144b (in line), supported by 25% YoY growth for DMart subsidiaries (including ecommerce).
- DMART added six stores (400k sqft area), taking the total to 377 stores (15.8m sqft). This implies the addition of average 66.7k sqft stores in 2Q (significantly higher than average store size addition of ~42k sqft).
- Consol. GP grew 16% YoY to INR21.5b (2% miss) as margins inched up ~25bp YoY to 14.9% (~25bp miss) on higher GM&A contribution (up 25bp YoY).
- Consol. EBITDA was up 9% YoY at INR10.9b (7% miss) as margins declined 40bp YoY to 7.6% due to weaker store productivity and increase in CoR.
- CoR increased 25% YoY, driven by 14% store area adds and ~9% YoY increase in CoR per sqft vs. average 5-6% increase. (Refer Exhibit 10)
- Consol. PAT grew 6% YoY to INR6.6b (11% miss) due to lower EBITDA and a higher tax rate. PAT margins declined 40bp YoY to 4.6%.
- For 1HFY25, DMART's consol. revenue was up ~16% YoY, while 1H EBITDA and PAT were up 14% and 12% YoY respectively. Based on our estimates, the implied revenue/EBITDA/PAT growth for 2HFY25 is ~15% / 17% / 16%.

14 October 2024



GM&A recovery continued, while FMCG growth moderated

- **GM&A:** The recovery continued in the General Merchandise and Apparel (GM&A) category, with ~17% YoY growth in 1H (vs. ~15% YoY in FY24), with category's share in the revenue mix improving further to 23.5% (vs. 22.3% in FY24, but still below ~25% in 1HFY23). A higher share of GM&A likely boosted gross margin. **Food:** DMart's largest category, food, saw a slight moderation in growth to ~17% (vs. ~20% YoY in FY24) and accounted for 56.4% of total revenue in 1H (vs. 57% in FY24).
- Non-food FMCG: Non-food FMCG was the most impacted category as growth moderated to ~13% YoY in 1H (vs. 17% YoY in FY24). Its share in the revenue mix declined ~50bp to 20.2% (vs. 20.7% in FY24).
- **LFL:** DMART reported 7.4% LFL growth for 2+ year old stores in 1HFY25 (vs. ~10% YoY in FY24), but growth moderated further to ~5.5% YoY in 2Q.
- **Bill cuts:** Total bill cuts increased ~16% YoY to 171m in 1HFY25, but growth moderated to ~13% YoY in 2Q.
- **ABV:** The average basket value (ABV) was stable YoY at INR1,624 in 1HFY25 and was up ~1% YoY at INR1,653 in 2Q.
- **DMart Ready:** DMART management indicated that the impact of online grocery formats, including DMart Ready, was clearly visible in 2Q, especially in large metro DMART stores. DMart Ready business was up ~22% YoY in 1HFY25, with its presence increasing to 24 cities (Nashik added in 1HFY25).

Capex increased sharply, likely on higher land acquisition

- DMART's OCF stood at INR9.2b, up +15% YoY, while cash capex increased sharply by ~22% YoY to INR15.9b (vs. ~INR27b in FY24), possibly on higher land acquisition.
- With higher cash capex offsetting the OCF improvement, 1HFY25 FCF (post interest and leases) stood at negative INR6.8b.
- Net cash decreased from INR12.3b in 2QFY24 to INR4b in 2QFY25.
- WC days increased slightly by 3 days to 31 days due to higher inventory days.
- DMART reported annualized ROE/ROCE of 15.2%/19.2% in 1HFY25 (vs. 15.1%/19.1% in FY24).

Valuation and view

- DMART's revenue growth remains dependent on its ability to add store area. With the increase in capex, we believe store additions can pick up pace starting 2HFY25. We model 40/45/50 store additions in FY25/FY26/FY27.
- DMART's LFL growth has been recently impacted by a moderation in inflation and a fast ramp-up of quick commerce services. We would watch out for impact of quick commerce on DMART's LFL growth and the ramp-up in DMart Ready over the next few quarters.
- We lower our FY25/FY26 revenue estimates by 2/4% as weaker store productivity partly offsets higher store additions. We reduce our FY25/FY26 EBITDA estimates by 6%/10% and EPS by 8%/14% on lower store productivity and higher CoR. We estimate a CAGR of 17%/20% in revenue/PAT over FY24-27, aided by 13/4% growth in footprints/revenue productivity and ~50bp margin improvement.
- We assign a 51x EV/EBITDA multiple (implies ~83x PE) on Dec'26E basis, in line with DMART's long-term 1-yr forward multiples to arrive at a TP of INR5,300. The stock is currently trading ~10% below its LT average multiples. We reiterate our BUY rating on the stock.



2.5 14.4

17.2

22.4

Consolidated - Quarte	erly Earning	S										(INR b)
Y/E March		FY24			FY25E			FY25E			FY25	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E	2QE	Var. (%)
Revenue	118.7	126.2	135.7	127.3	140.7	144.4	156.9	146.5	507.9	588.5	144.6	(0.1)
YoY Change (%)	18.2	18.7	17.3	20.1	18.6	14.4	15.6	15.1	18.6	15.9	14.6	
Total Expenditure	108.3	116.2	124.5	117.8	128.5	133.5	143.8	135.4	466.9	541.2	132.9	0.5
EBITDA	10.4	10.0	11.2	9.4	12.2	10.9	13.1	11.1	41.0	47.3	11.7	(6.9)
EBITDA margin (%)	8.7	8.0	8.3	7.4	8.7	7.6	8.3	7.6	8.1	8.0	8.1	
Change YoY (%)	2.7	12.7	16.0	22.3	18.0	8.8	16.8	17.8	12.8	15.4	16.9	
Depreciation	1.6	1.7	1.9	2.0	1.9	2.1	2.2	2.7	7.3	8.9	2.1	(1.1)
Interest	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.6	0.7	0.2	2.3
Other Income	0.4	0.4	0.3	0.4	0.4	0.3	0.4	0.3	1.5	1.5	0.4	
PBT	9.0	8.5	9.5	7.6	10.5	9.0	11.1	8.6	34.6	39.3	9.9	(8.4)
Tax	2.4	2.3	2.6	2.0	2.8	2.4	2.8	2.3	9.3	10.4	2.5	
Rate (%)	26.6	26.8	27.2	26.2	26.6	27.0	25.5	27.1	26.7	26.5	25.2	
Reported PAT	6.6	6.2	6.9	5.6	7.7	6.6	8.2	6.3	25.4	28.9	7.4	(10.6)
Adj PAT	6.6	6.2	6.9	5.6	7.7	6.6	8.2	6.3	25.4	28.9	7.4	(10.6)


17.5 5.8

19.3

11.5

13.3 13.8 18.4

YoY Change (%)
E: MOFSL Estimates



Buy



CIE Automotive India

 BSE SENSEX
 S&P CNX

 81,381
 24,964



Bloomberg	CIEINDIA IN
Equity Shares (m)	379
M.Cap.(INRb)/(USDb	205.3 / 2.4
52-Week Range	628 / 401
1, 6, 12 Rel. Per (%)	-2/4/-9
12M Avg Val (INR M)	285
Free float (%)	34.3

Financials & Valuations (INR b)


V/E 84	CV22	CVOAF	CVOEE
Y/E March	CY23	CY24E	CY25E
Sales	92.8	90.7	103.5
EBITDA (%)	15.3	15.1	15.7
Adj. PAT	8.0	8.2	10.1
EPS (INR)	21.1	21.7	26.8
EPS Growth (%)	16.8	2.7	23.6
BV/Share (Rs)	158	175	195
Ratio			
RoE (%)	14.4	13.0	14.5
RoCE (%)	13.0	12.0	13.7
Payout (%)	23.8	20.0	20.0
Valuations			
P/E (x)	25.7	25.0	20.2
P/BV (x)	3.4	3.1	2.8
Div. Yield (%)	0.9	0.8	1.0
FCF Yield (%)	4.2	1.9	3.4

Shareholding Pattern (%)

As On	Jun-24	Mar-24	Jun-23
Promoter	65.7	65.7	65.7
DII	19.5	18.2	14.8
FII	5.0	5.1	7.5
Others	9.8	11.0	12.0

FII includes depository receipts

Stock Performance (1-year)



Profitability to maintain as growth moderates

TP: INR650 (+20%)

Profitability to maintain as growth moderates

India to remain a key growth driver in the near term

CMP: INR541

We recently met with the management of CIE Automotive (CIEINDIA), and following are the KTAs from the discussion. The domestic market is experiencing a weak demand phase in the tractor and PV segments, while 2W continues to perform relatively well. The global auto market, particularly in Europe, remains sluggish. The EV transition in India continues to evolve as a growth opportunity, given the healthy new order wins. Additionally, the risk of EV transition in Europe remains mitigated, given that: 1) most European OEMs are now reconsidering their EV transition deadlines and 2) hybrids are likely to gain traction in Europe, which augurs well for CIEINDIA. However, the management remains committed to focusing on: 1) outperforming the core domestic industry growth in the long run; 2) further improving operational efficiencies in India; and 3) revising costs in Europe to the new normal. Given its focus on operational efficiencies, CIEINDIA has evolved into a highly resilient company. Some of the financial attributes unique to the global ancillary player include: being net debt free, having strict capex/inorganic expansion guidelines, generating positive FCF, and tracking an improving return trajectory. We reiterate BUY with a TP of INR650 (based on ~21x Sep'26E consol. EPS).

Well-diversified company with unique capabilities

CIEINDIA is well-diversified, notable for being the only company that houses seven different automotive technologies under one roof. Moreover, it is amongst the top 2-3 suppliers in each of the technologies it supplies. Some of its strong attributes include: 1) the largest supplier of PV crankshafts in India; 2) a dominant player in forged steering parts; 3) one of the two strategic suppliers of aluminum castings to a leading domestic 2W OEM; 4) the second-largest supplier of crankshafts in Europe; 5) a strategic supplier of gears to a global leading supplier of construction and mining equipment; 6) the largest supplier of stampings and gears to one of the leading SUV/tractor OEMs in India; and 7) a supplier with the unique ability to supply crankshafts through both castings and forgings.

India: Outlook appears weak, with 2Ws as the only bright spot

The management has indicated that demand remains weak across most segments in India, including PVs, CVs, and tractors. However, the demand for 2Ws continues to be healthy. While the demand for tractors is expected to revive in H2, it is yet to pick up. However, M&M (UVs) and BJAUT, which are its key customers, are currently experiencing healthy demand trends on account of their new model launches.



CIEINDIA will continue to outperform core industry growth

CIEINDIA aims to continue outperforming the domestic auto industry growth by 5-7% in the long- run. As highlighted above, its anchor customers, such as M&M and BJAUT, continue to experience strong demand traction. CIEINDIA is featured in most of M&M's upcoming and recently launched models. Additionally, it has a strong presence in Bajaj's recent new launches. Apart from its anchor customers, CIEINDIA has around 10-12 growth customers, each contributing to about 3-6% of its revenues. CIEINDIA experiences a healthy demand traction from these customers and targets to ramp up its presence in this area. Additionally, the company's growth is expected to be driven by new opportunities emerging from the transition to EV and hybrid technologies.

Europe: Industry outlook likely to remain weak at least in the near term

The automotive demand in EU remains weak, primarily due to uncertainties surrounding the transition to EVs, according to the management. With many OEMs reevaluating their EV transition strategies, there is significant uncertainty among customers about whether to opt for EVs or ICE vehicles, which the management cites as a reason for the weak demand. Although the company has orders in hand, delays in execution by OEMs are adversely affecting its revenue traction from the region. The market is expected to experience a 7-8% decline this year, with 2HCY24 expected to perform worse than 1H and even weaker than the usual H2 levels.

Electrification in India opens up new growth avenues

About 20% of CIEINDIA's business involves crankshafts or other engine-related components for 4Ws and 2Ws. Another 50% of this comes from PV EVs. Since the EV transition in PVs is expected to take longer in India, the company's exposure to engine components is fairly limited in the country. Nevertheless, the management views the EV transition as an opportunity rather than a threat, given its multiple new order wins in the Indian segment. The company is engaged in 3W EVs with its largest customer. It also has a strong presence with two of the four largest PV EV OEMs in India. Further, the company has garnered a fair share of orders from 2W EV OEMs in the country. As of H1CY24, CIEINDIA's EV order book contributed ~30% to India's overall order book. While EV transition in India remains a strong growth opportunity for CIEINDIA, it is important to note that the EV penetration in the country is progressing much more slowly than envisaged.

Slow pace of electrification in EU and emergence of hybrid to bode well

In Europe, 4W forgings contribute EUR275m-EUR300m to CIEINDIA's revenue (~81% of EU's revenue), approximately half of which comes from crankshafts. Thus, the rapid EV transition in Europe is certainly a risk for the company's European business in the long run. However, while the current EV penetration in Europe has reached 12%, most OEMs are reworking/postponing their EV transition plans following multiple headwinds in this segment. Given these trends, OEMs are likely to focus on pushing hybrids as a temporary solution before the EV transition picks up pace again. Nonetheless, almost 55% of its H1 order book in Europe was from EVs. The company is also looking to ramp up its presence in aluminum forgings by showcasing its capabilities to multiple global OEMs. Thus, the EV transition risk in Europe for CIEINDIA appears to have materially subsided and the company would



continue to focus on diversifying its revenue stream, in turn mitigating any material impact on its financials in the long run.

Focus on optimizing growth and profitability

While the management is confident in achieving long-term outperformance relative to the broader industry, it acknowledges the near-term challenges posed by weak demand in both domestic markets and Europe, as highlighted above. However, the company will continue to emphasize prioritizing profitability over simply maintaining topline growth. The management has indicated that it will not pursue growth without ensuring a requisite level of profitability. In India, the company aims to continue increasing margins by enhancing its operational efficiencies. CIEINDIA's parent company specializes in automation/digitization initiatives globally. It incentivizes production managers and measures their performance, not only on the production output but also on the ROI delivered from their respective plants. Given these practices, notably, the company's margins in Europe are comparable to, or even better than, those in India. Despite the weak industry demand outlook in Europe, the management aims to sustain margins at current levels in Europe. It targets to achieve this by revisiting all cost heads to new utilization levels.

Other takeaways

- The company's capex has been in the range of 5-6% of its revenue. It targets to invest INR 15b over the next three years. A bulk of its capex would be invested in India, where it is receiving new orders. In Europe, no additional growth capex is required as utilization remains around 80%.
- CIEINDIA has evolved into a highly resilient company. Even at the peak of COVID-19, its margins did not fall below 9%.

Valuation and view

■ We expect the Indian business to be the primary growth driver for the company in the near future. However, the weak outlook for its EU business and Metalcastello is likely to weigh on the overall performance in the near term. The company will continue to strive to enhance efficiencies in the coming years. Some of the financial attributes unique to the global ancillary player include: being net debt free, having strict capex/inorganic expansion guidelines, generating positive FCF, and tracking an improving return trajectory. The stock trades at 25x/20x CY24E/CY25E consolidated EPS. We reiterate BUY with a TP of INR650 (based on ~21x Sep'26E consol. EPS).



Price-to-book (one-year forward) P/B (x) Max (x) Avg (x) Min (x) +1SD - -1SD 5.0 4.4 3.8 3.1 2.5 2.2 1.4 1.3 0.0 Jun-23 Sep-24 Mar-17 Jun-18 Dec-20 Dec-15 Sep-19 Mar-22

Source: MOFSL, Company Source: MOFSL, Company



Fund Folio

Fund Folio: Equity AUM crosses ~INR33t – another crest amid volatilities


Key observations

- The Nifty surpassed the 26k mark in Sep'24 to hit a record high of 26,277 before ending 2.3% higher MoM at 25,811. The index has closed higher for the fourth straight month now. Notably, the index was extremely volatile and swung around 1,524 points before closing 575 points higher. FIIs were net buyers at USD5.9b the highest since Jan'24. DII inflows remained strong at USD3.8b in Sep'24.
- Equity AUM of domestic MFs (including ELSS and index funds) increased 3.3% MoM to INR33.8t in Sep'24, led by a rise in market indices (Nifty up 2.3% MoM) and an increase in sales of equity schemes (up 3.7% MoM to INR838b). However, the pace of redemptions increased to INR474b (up 20.6% MoM). Consequently, net inflows moderated by 12.3% to INR364b in Sep'24 from INR415b in Aug'24.
- Total AUM of the MF industry inched up 0.6% MoM to INR67.1t in Sep'24, driven by a MoM increase in AUM of equity funds (INR1,074b), balanced funds (INR167b), and other ETFs (INR159b). Conversely, AUM of liquid and income funds declined by INR917b and INR124b MoM, respectively.
- Investors continued to park their money in mutual funds, with inflows into systematic investment plans (SIPs) reaching a new peak of INR245.1b in Sep'24 (up 4.1% MoM and 52.8% YoY).

Some interesting facts

- The month saw notable changes in the sector and stock allocation of funds. On a MoM basis, the weights of Private Banks, Metals, Retail, Automobiles, Consumer, Utilities, and Consumer Durables increased, while those of Technology, Oil & Gas, Capital Goods, Healthcare, and PSU Banks moderated.
- Private Banks' weight, after touching a ~six-year low in Aug'24, climbed in Sep'24 to 16.1% (+20bp MoM; 260bp YoY).
- Metals, after declining for three consecutive months, saw a rise in weight to 2.7% (+20bp MoM, +40bp YoY) in Sep'24.
- Technology's weights, after a three consecutive rise, moderated in Sep'24 to 8.8% (-40bp MoM; -60bp YoY).
- Oil & Gas weight declined for the sixth consecutive month to a nine-month low of 6.2% (-30bp MoM, +40bp YoY) in Sep'24.
- In terms of value increase MoM, six of the top-10 stocks were from the Private Banks and Automobile verticals: HDFC Bank (+INR154.3b), M&M (+INR54.2b), Axis Bank (+INR47b), Maruti Suzuki (+INR44b), ICICI Bank (+INR42.8b), and Samvardhana Motherson (+INR39.6b).

Monthly trends in sales, redemptions, and net amount raised by MFs (equity)







Insurance Tracker

Individual WRP for private players grows 28% YoY in Sep'24

Overall individual WRP rises 34% YoY; LIC's individual WRP up 48% YoY

- In Sep'24, the individual weighted received premium (WRP) growth for private players stood at 28% YoY vs. the industry growth of 34% YoY. However, LIC surpassed industry growth, at 48% YoY (flat YoY in Aug'24).
- Among listed players, individual WRP for IPRULIFE/Bajaj Allianz/ MAXLIFE/HDFCLIFE/ SBILIFE grew 33%/34%/38%/25%/9% YoY. Tata AIA grew 60% YoY.
- Individual WRP for LIC grew 48% YoY in Sept'24 (flat YoY in Aug'24).
- IRDAI recently announced new regulations regarding surrender values, to be implemented from 1st Oct'24. The product and commission construct could undergo notable changes, leading to volatility in premium growth for the rest of FY25.

 Nevertheless, over the medium term, we believe these changes are favorable for customers and will bring back growth. HDFCLIFE and SBILIFE are our preferred picks in the space.

Individual WRP and YoY growth (%)

Individual WRP, INR m	Sept'24	YoY gr. (%)
Grand Total	1,20,143	34.1
Total Private	78,290	27.8
LIC	41,854	47.7
Total Public	41,854	47.7
SBI Life	16,279	9.1
HDFC life	11,709	25.2
Tata AIA	9,303	59.7
Max Life	7,855	38.3
ICICI Prudential	7,454	32.6
Bajaj Allianz	6,693	34.0
Birla Sun life	3,757	64.7
Kotak Life	2,698	44.0

Source: IRDAI, LIC Council, MOFSL Note - *including Excide life

On an individual WRP basis, market share of LIC increases MoM

In terms of individual WRP, the market share of private players decreased ~545bp MoM to 65.2% in Sep'24. LIC's market share increased to 34.8% in Sep'24 from 29.4% in Aug'24. On the YTD basis, the market share of private players declined 70bp YoY to 67.6%. LIC's YTD market share stood at 32.4%. For Sep'24, SBILIFE remained the largest private insurer in terms of market share in individual WRP, followed by HDFCLIFE at 9.7% and Tata AIA at 7.7%. On an un-weighted premium basis, HDFCLIFE was the largest private insurer, with a market share of 6.7%, followed by IPRU Life (4.2%) and SBI Life (4%).

Performance of key private players

On an individual WRP basis, the combined market share of the listed players – SBILIFE, HDFCLIFE, IPRU, and MAXLIFE – accounted for 55.3% of the private insurance industry and 36% of overall industry share as of Sep'24. Among the prominent private insurers, TATA AIA at INR9.3b surpassed IPRULIFE at INR7.5b in Sep'24 and secured the third position in terms of individual WRP, while Max Life held the fourth position at INR7.9b, in Sep'24. Bajaj Allianz stood at the sixth position at INR6.7b. Among key listed players on the basis of individual WRP –

- **HDFCLIFE** (including Exide merger) grew 25.2% YoY in Sep'24 (up 28.4% YoY YTD FY25). Total un-weighted premium grew 9.1% YoY (up 11.8% YoY YTD FY25).
- **SBILIFE** rose 9.1% YoY in Sep'24 (up 14.7% YoY in YTD FY25). Total un-weighted premium rose 4.6% YoY in Sep'24 (down 3.3% YoY in YTD FY25).
- IPRU grew 32.6% YoY in Sep'24 (up 39.2% YoY in YTD25). Total un-weighted premium was up 20.6% YoY in Sep'24 (up 17.4% YoY in YTD FY25).
- MAXLIFE grew 38.3% YoY in Sep'24 (up 31% YoY in YTD FY25). Total unweighted premium grew 29% YoY in Sep'24 (up 19% YoY in YTD FY25).



Un-weighted new business premium and growth

		YoY		YoY		YoY
INR m	Sept'24	Growth	FY25YTD	growth	FY24	growth
Grand Total	3,50,203	14.0%	18,92,138	19.5%	37,79,584	1.9%
LIC	2,03,693	12.4%	11,55,499	24.7%	22,25,230	-4.2%
Total Private	1,46,510	16.4%	7,36,639	12.1%	15,54,354	12.0%
SBI Life	29,918	4.6%	1,57,240	-3.3%	3,82,385	28.9%
HDFC life	26,705	9.1%	1,47,069	11.8%	2,99,881	3.7%
ICICI Prudential	16,599	20.6%	86,976	17.4%	1,80,805	6.8%
Tata AIA	12,114	74.8%	44,539	22.9%	88,972	4.2%
Max Life	11,314	29.0%	50,887	19.0%	1,10,201	22.7%
Bajaj Allianz	10,524	-8.3%	57,408	15.4%	1,14,926	7.0%
Birla Sunlife	10,252	78.0%	47,129	42.8%	80,997	5.5%
Kotak Life	7,618	40.7%	34,584	7.8%	86,568	12.5%
PNB Met Life	3,694	30.3%	18,292	32.4%	34,100	5.9%

Note-* including Excide Life Source: IRDAI, LIC Council, MOFSL

Individual WRP, growth, and market share

		YoY	Market		YTD	Market		YoY	Market
INR m	Sept'24	growth	share	FY25YTD	growth	share	FY24	growth	share
Grand Total	1,20,143	34.1%	100.0%	5,26,861	20.6%	100.0%	10,89,752	4.8%	100.0%
Total Private	78,290	27.8%	65.2%	3,56,000	23.9%	67.6%	7,38,711	8.0%	67.8%
Total Public	41,854	47.7%	34.8%	1,70,861	14.4%	32.4%	3,51,041	-1.4%	32.2%
SBI Life	16,279	9.1%	13.5%	80,938	14.7%	15.4%	1,72,344	13.2%	15.8%
HDFC life	11,709	25.2%	9.7%	57,884	28.4%	11.0%	1,13,764	4.1%	10.4%
Tata AIA	9,303	59.7%	7.7%	36,333	26.6%	6.9%	74,133	4.5%	6.8%
Max Life	7,855	38.3%	6.5%	33,086	31.0%	6.3%	69,608	15.5%	6.4%
ICICI Prudential	7,454	32.6%	6.2%	36,660	39.2%	7.0%	72,135	7.1%	6.6%
Bajaj Allianz	6,693	34.0%	5.6%	31,868	30.7%	6.0%	63,248	21.3%	5.8%
Birla Sun life	3,757	64.7%	3.1%	15,781	32.8%	3.0%	30,747	1.7%	2.8%
Kotak Life	2,698	44.0%	2.2%	10,026	16.8%	1.9%	28,228	3.4%	2.6%
Canara HSBC OBC	2,046	18.1%	1.7%	8,567	41.9%	1.6%	17,024	2.7%	1.6%

Source: IRDAI, LIC Council, MOFSL Note- * including Excide Life

Market share among private players based on un-weighted and individual WRP

INR m	U	n-weighted premiu	ms		Individual WRP	
(%)	Sept'24	FY25YTD	FY24	Sept'24	FY25YTD	FY24
Grand Total	3,50,203	18,92,138	37,79,584	1,20,143	5,26,861	10,89,752
Total Private	1,46,510	7,36,639	15,54,354	78,290	3,56,000	7,38,711
SBI Life	20.4%	21.3%	24.6%	20.8%	22.7%	23.3%
HDFC Standard	18.2%	20.0%	19.3%	15.0%	16.3%	15.4%
ICICI Prudential	11.3%	11.8%	11.6%	9.5%	10.3%	9.8%
Tata AIB	8.3%	6.0%	5.7%	11.9%	10.2%	10.0%
Max Life	7.7%	6.9%	7.1%	10.0%	9.3%	9.4%
Bajaj Alllianze	7.2%	7.8%	7.4%	8.5%	9.0%	8.6%
Birla Sun life	7.0%	6.4%	5.2%	4.8%	4.4%	4.2%
Kotak Life	5.2%	4.7%	5.6%	3.4%	2.8%	3.8%
PNB Met Life	2.5%	2.5%	2.2%	2.2%	2.9%	3.1%
Canara HSBC OBC	2.3%	1.9%	1.8%	2.6%	2.4%	2.3%

Source: IRDAI, LIC Council, MOFSL





Performance of top companies in Sep'24

Company	MAT growth (%)	Sep'24 (%)
IPM	7.7	5.1
Abbott*	8.4	6.3
Ajanta	9.6	10.8
Alembic	2.8	-5.1
Alkem*	4.8	1.3
Cipla	7.4	5.6
Dr Reddy's	9.0	7.9
Emcure*	6.4	3.8
Eris	7.3	1.5
Glaxo	0.8	-2.8
Glenmark	12.3	9.6
Intas	12.2	10.2
Ipca	14.2	7.7
JB Chemical*	11.3	15.5
Lupin	7.7	5.4
Macleods	7.7	-1.5
Mankind	9.0	5.1
Sanofi	5.7	0.5
Sun*	9.4	7.5
Torrent	8.6	7.0
Zydus*	6.9	6.8

Acute therapies drag overall IPM growth for Sep'24

- The Indian Pharma Market (IPM) grew 5.1% YoY in Sep'24 (vs. 7.6% in Aug'24 and 8.9% in Sep'23).
- Cardiac/Derma/Anti-diabetic therapies grew at 9.7%/8.3%/7.7%, while slower growth was experienced by Respiratory/AI, which declined 1.1%/0.3% YoY.
- For the 12 months ending in Sep'24, IPM grew 7.7% YoY, led by price growth/new launches, which contributed 4.2%/2.7% YoY to the overall growth. However, volume growth was moderate at 0.8% YoY in Sep'24.
- IPM's top brand, Augmentin, experienced a decline of 2% YoY to INR730m with a market share of 0.4% in Sep'24.
- Out of the top 10 brands, Udiliv/Thyronorm clocked 16.5%/10.2% YoY growth of INR569/INR572m in Sep'24.

JB Chemical/Ajanta/Intas outperform in Sep'24

- In Sep'24, JB Chemical (up 15.5% YoY), Ajanta Pharma (up 10.8% YoY), and Intas (up 10.2% YoY) recorded notably higher growth rates than IPM.
- **JB Chemical** outperformed IPM, led by a low base and strong performance across the top four therapies in Sep'24.
- **Glenmark** outperformed IPM, led by a strong performance across the top four therapies, offset by a decline in respiratory therapies in Sep'24.
- Intas outperformed IPM, led by double-digit growth in Neuro/Antidiabetic/Pain.
- **IPCA** reported industry-leading volume/price growth of 7.4%/5.8% YoY on MAT basis. Eris posted the highest growth in new launches (up 5% YoY).
- Sun Pharma, with a market share of 7.7%, grew 7.5% YoY (+250bp vs. IPM), driven by double-digit growth of 14.7%/14.5%/10.5% in Pain/Antidiabetic/VMN.
- Alkem continued to underperform in the IPM owing to high acute share (~82%), growing at 1.3% YoY in Sep'24. The slow growth can be attributed to 6.3% decline experienced by Anti-infectives (36% of the total Alkem revenue).

Cardiac/Gastro/Neuro lead YoY growth on MAT basis


- Acute therapies grew at a modest rate of 3% YoY, while chronic therapies grew at 8% YoY for Sep'24. The share of acute therapies segment in the overall IPM stood at 61.3% for MAT in Sep'24, with YoY growth of 3%. The chronic therapies segment (38.7% of IPM) grew 8% YoY.
- Cardiac/Derma /Anti-diabetic grew 9.7%/8.3%/7.7%% YoY.
- Gynaec/Pain/VMN underperformed in the IPM by 390bp/50bp/10bp, while Respiratory/Al declined 1.1%/0.3% in Sep'24.

India and MNC pharma experience growth moderation in Aug'24

- As of Sep'24, Indian pharma companies held a majority share of 84% in IPM, while the remaining was held by multinational pharma companies.
- Both MNCs and Indian companies registered single-digit growth QoQ in Sep'24.
- In MNCs, Abbott registered the highest growth of 6.3% YoY, while Sanofi registered a flat growth of 0.5% in Sep'24.




IPM exhibited 5% YoY growth in Sep'24




Source: MOFSL, IQVIA

Acute and chronic therapies registered YoY growth of 3%/8% in Sep'24



Source: MOFSL, IQVIA

Both Indian firms as well as MNCs witnessed single-digit YoY growth in Sep'24



Source: MOFSL, IQVIA





Aug'24 IIP down to a 22-month low

Led by an elevated base and heavy rainfall

- IIP contracted 0.1% YoY in Aug'24 (vs. 4.7% in Jul'24, reduced from 4.8%), mainly led by an elevated base and excessive rainfall in parts of the country. The number was lower than the consensus estimate of 1% and our expectation of 1.5%. The contraction in growth was broad-based. All the three sectors witnessed a sharp deceleration in growth with mining and electricity posting contraction.
- The growth in the manufacturing sector slowed down to a 22-month low of 1% in Aug'24 vs. 4.4% in Jul'24 and 10% in Aug'23. The details of the manufacturing sector suggest that 77% of the items within the sector grew at a slower rate compared to last year (vs. 54% in Jul'24), 87% of the items grew at a rate less than 5% (vs. 34% in Jul'24), and 49% of the items posted contraction (vs. 17% in Jul'24). At the same time, mining output contracted 4.3% in Aug'24, worst in the last 42 months (vs. 3.8% in Jul'24 and 12.3% in Aug'23). Further, the growth in electricity output contracted 3.7% in Aug'24 vs. 7.9% in Jul'24 and 15% in Aug'23.
- According to the use-based classification, the growth in the output of infra & construction goods decelerated to a 9-month low of 1.9% in Aug'24 (vs. 4.6% in Jul'24 and 15.7% in Aug'23). At the same time, capital goods decelerated to 0.7% in Aug'24 (lowest in nine months). Additionally, the consumer goods output contracted 0.5% in Aug'24 (lowest in 14 months) vs. a growth of 0.6% in Jul'24. Within the consumer goods category, the growth of consumer durables was decent, though the pace of growth was slow (5.2% in Aug'24), while consumer non-durables output posted its third consecutive contraction in Aug'24 (-4.5% vs. -4.4% in Jul'24).
- IIP contracted 0.1% YoY in Aug'24 on account of an adverse base effect and the impact of excessive rainfall on mining and electricity output. The number was much lower than expected. In Apr'24-Aug'24, this fiscal, IIP grew 4.2% against 6.2% in the year-ago period. We believe that GDP growth would slow down to 6.2% in 2QFY25, which is reinforced by the slowdown in industrial output activity.

Industrial output contracted in Aug'24

- Industrial output contracted to a 22-month low in Aug'24: IIP contracted 0.1% YoY in Aug'24 (vs. 4.7% in Jul'24, reduced from 4.8%), mainly led by an elevated base and excessive rainfall in parts of the country. The number was lower than the consensus estimate of 1% and our expectation of 1.5%. The contraction in growth was broad-based. All the three sectors witnessed a sharp deceleration in growth with mining and electricity posting contraction. (Exhibit 1).
- Contraction in growth was broad-based: The growth in the manufacturing sector slowed down to a 22-month low of 1% in Aug'24 vs. 4.4% in Jul'24 and 10% in Aug'23. The details of the manufacturing sector suggest that 77% of the items within the sector grew at a slower rate compared to last year (vs. 54% in Jul'24), 87% of the items grew at a rate less than 5% (vs. 34% in Jul'24), and 49% of the items posted a contraction (vs. 17% in Jul'24). (Exhibit 4).
- At the same time, mining output contracted 4.3% in Aug'24, worst in the last 42 months (vs. 3.8% in Jul'24 and 12.3% in Aug'23). Further, the growth in electricity output contracted 3.7% in Aug'24 vs. 7.9% in Jul'24 and 15% in Aug'23. (Exhibit 2).
- Growth of capital goods and infra & construction goods decelerated sharply in Aug'24: According to the use-based classification, the growth in the output of infra & construction goods decelerated to a 9-month low of 1.9% in Aug'24 (vs. 4.6% in Jul'24 and 15.7% in Aug'23). At the same time, capital goods decelerated to 0.7% in Aug'24 (lowest in nine months). Additionally, the consumer goods



output contracted 0.5% in Aug'24 (lowest in 14 months) vs. a growth of 0.6% in Jul'24. Within the consumer goods category, the growth of consumer durables was decent, though the pace of growth was slower (5.2% in Aug'24), while consumer non-durables output posted its third consecutive contraction in Aug'24 (-4.5% vs. -4.4% in Jul'24). (Exhibit 3).

Our view: IIP contracted 0.1% YoY in Aug'24 on account of the adverse base effect and the impact of excessive rainfall on mining and electricity output. The number was much lower than expected. In Apr'24-Aug'24, this fiscal, IIP grew 4.2% against 6.2% in the year-ago period. We believe that GDP growth would slow down to 6.2% in 2QFY25, which is reinforced by the slowdown in industrial output activity.

Exhibit 1: IIP growth contracted 0.1% YoY in Aug'24...





Exhibit 2: ... the contraction in growth was broad-based



Source: CSO, MOFSL Source: CSO, MOFSL

Exhibit 3: Capital goods and infra & construction goods output witnessed a sharp deceleration in Aug'24





Exhibit 4: 49% of the manufacturing basket posted contraction in Aug'24 vs. 17% in Jul'24



Source: CSO, MOFSL Source: CSO, MOFSL



Exhibit 5: Key components of IIP

% YoY	Weight	FY21	FY22	FY23	FY24	Aug-23	June-24	Jul-24	Aug-24
Industry-based classification									
Mining	14.4	(7.8)	12.2	5.8	7.5	12.3	10.3	3.8	(4.3)
Manufacturing	77.6	(9.6)	11.7	4.7	5.4	10.0	3.2	4.4	1.0
Electricity	8.0	(0.5)	8.0	8.9	7.0	15.3	8.6	7.9	(3.7)
IIP	100.0	(8.5)	11.4	5.3	5.9	10.9	4.7	4.7	(0.1)
Use-based classification									
Primary Goods	34.0	(7.0)	9.6	7.5	6.1	12.4	6.3	5.9	(2.6)
Capital Goods	8.2	(18.7)	17.0	13.0	6.2	13.1	3.8	11.8	0.7
Intermediate Goods	17.2	(9.4)	15.4	3.8	6.2	7.4	3.0	6.4	3.0
Infrastructure/Construction	12.3	(8.7)	18.8	8.4	9.7	15.7	7.1	4.6	1.9
Consumer Goods	28.2	(7.3)	6.6	0.6	3.8	8.3	2.6	0.6	(0.5)
Durable Goods	12.8	(14.9)	12.4	0.6	3.6	6.0	8.7	8.3	5.2
Non-Durable Goods	15.3	(2.1)	3.2	0.7	4.0	9.9	(1.5)	(4.3)	(4.5)

Source: CSO, MOFSL







Birla Corp: Optimistic Of An Industry Wide Recovery In EBITDA/tn In Q4; Sandip Ghose, MD & CEO

- Cement sector experienced challenging 1H but there is cautious optimism in 2H influenced by festive months & socio-political factors
- Expect cement industry growth of 5%-7% in FY25
- Believe prices have bottomed out
- Seeing tailwinds on cost sides; cooling pet coke prices could positively impact in 2H



Wockhardt: Will Be Applying For Nafithromycin's Approval In Some Budget Markets; Habil Khorakiwala, Chairman

- Pneumonia drug approval expected in next 3 weeks; expect it to become Rs 400-500cr mkt over 4-5 yrs
- There is a 97% success rate in treatment for Nafithromycin 400 mg
- The drug will be available via prescriptions and not only in hospital settings



BLS International: Citizenship Invest Acquisition Brings In A Big Market Opportunity; Shikhar Aggarwal, CEO

- To acquire Citizenship Invest for a purchase consideration of Rs 260cr; will be funded through internal accuals
- This acquisition opens up significant market opportunities, as the global demand for second citizenship is rapidly increasing
- aims to leverage its extensive network to enhance growth and profitability in the coming years.



Britannia: Now In A Position To See How We Can Reduce Premium To Amul; Varun Berry, MD

- Inaugrated a new cheese factory in Maharashtra, a JV with BEL group
- Currently produces 6,000 tons of natural cheddar cheese and plans to double this capacity
- Aims to reduce the price premium of their products while maintaining product quality
- Aims to triple cheese biz in next 5 yrs to Rs 750-1000cr



Anand Rathi: Close To Reaching ₹1,000 Cr Per Month Of Net Flows; Feroze Azeez, Deputy CEO

- Raised AUM guidance from Rs 72k to Rs 80k
- Achieved 54% of FY25 revenue target
- PAT guidance raised from ₹280 Cr to ₹295 Cr
- Does not expect debt to return huge capital gains if RBI cuts rates
- Regulatory changes in F&O trading seen as beneficial for retail investors







		CMP	TP	% Upside		EPS (INR)	EPS	Gr. YoY	(%)	P/E	(x)	P/E	3 (x)	ROE	E (%)
Company	Reco	(INR)	(INR)	Downside		FY25E	FY26E	FY24		· ·	FY25E					
Automobiles		((,													
Amara Raja Ener.	Neutral	1407	1415	1	49.5	54.5	61.7	10.4	10.1	13.2	25.8	22.8	3.4	3.0	13.9	14.0
Apollo Tyres	Buy	505	630	25	28.7	25.4	33.2	77.3	-11.6	30.7	19.9	15.2	1.7	1.5	11.1	13.3
Ashok Ley.	Buy	228	275	21	9.1	10.9	13.2	102.5	19.5	21.3	20.9	17.2	6.5	5.5	33.6	34.8
Bajaj Auto	Neutral	11878	11450	-4	276.1	302.0	387.9	28.9	9.4	28.4	39.3	30.6	11.8	10.9	31.9	37.0
Balkrishna Inds	Neutral	3024	2840	-6	76.5	82.0	108.8	39.6	7.2	32.7	36.9	27.8	5.8	5.0	16.8	19.5
Bharat Forge	Neutral	1492	1465	-2	19.7	33.4	44.3	61.8	69.1	32.7	44.7	33.7	8.6	7.3	20.4	23.4
Bosch	Neutral	38502	34275	-11	620.5	731.6	877.2	28.5	17.9	19.9	52.6	43.9	8.6	7.8	17.1	18.7
CEAT	Buy	3009	3695	23	169.4	145.0	193.4	226.6	-14.4	33.4	20.8	15.6	2.7	2.4	13.7	16.2
Craftsman Auto	Buy	6231	7475	20	144.2	144.4	223.1	22.6	0.2	54.5	43.2	27.9	4.7	4.1	14.3	15.6
Eicher Mot.	Sell	4726	4095	-13	146.3	161.1	175.7	37.3	10.1	9.0	29.3	26.9	6.2	5.4	22.6	21.4
Endurance Tech.	Buy	2344	2760	18	47.3	61.9	74.3	36.5	30.9	20.0	37.9	31.6	5.8	5.0	16.3	17.1
Escorts Kubota	Neutral	3937	4085	4	94.9	99.9	127.4	85.0	5.3	27.5	39.4	30.9	4.7	4.2	12.7	14.4
Exide Ind	Neutral	530	470	-11	12.4	13.7	16.8	16.5	10.4	22.8	38.8	31.6	3.2	3.0	8.3	9.4
Happy Forgings	Buy	1128	1375	22	25.8	30.5	42.7	10.6	18.4	39.9	36.9	26.4	5.7	4.9	16.6	19.9
Hero Moto	Buy	5477	6625	21	204.6	230.3	280.1	40.5	12.6	21.6	23.8	19.6	5.7	5.3	24.8	28.0
M&M	Buy	3135	3610	15	88.7	103.0	122.7	34.0	16.0	19.2	30.4	25.5	6.1	5.1	21.6	21.8
CIE Automotive	Buy	541	650	20	21.1	21.7	26.8	16.8	2.7	23.6	25.0	20.2	3.1	2.8	13.0	14.5
Maruti Suzuki	Buy	12774	15235	19	429.0	475.1	550.4	56.8	10.7	15.9	26.9	23.2	4.2	3.7	15.6	16.0
MRF	Sell	132288	107790	-19	4,990.2	4,745.7	5,546.8	175.2	-4.9	16.9	27.9	23.8	3.0	2.7	11.4	12.0
Samvardh. Motherson	Buy	213	240	13	3.7	6.3	8.4	63.6	71.3	32.3	33.5	25.3	4.9	4.3	15.5	18.3
Motherson Wiring	Buy	66	83	26	1.4	1.6	2.1	31.1	12.1	27.6	40.7	31.9	14.3	11.6	38.5	40.0
Sona BLW Precis.	Neutral	665	670	1	8.9	10.2	13.2	31.6	14.5	28.6	64.9	50.5	12.2	10.5	20.1	22.4
Tata Motors	Neutral	931	990	6	58.7	57.1	69.5	2,628.0	-2.7	21.7	16.3	13.4	3.3	2.7	22.2	22.0
TVS Motor	Neutral	2793	2610	-7	43.8	52.5	67.9	44.4	19.6	29.4	53.2	41.1	13.5	10.7	28.4	29.0
Tube Investments	Buy	4223	5040	19	34.4	60.6	74.4	-15.2	76.3	22.8	69.7	56.7	13.2	10.8	20.8	21.0
Aggregate								94.5	9.4	21.8	31.7	29.0	6.1	5.3	19.4	18.4
Banks - Private																
AU Small Finance	Buy	691	830	20	23.0	30.6	38.8	4.3	33	26.5	22.5	17.8	3.1	2.6	14.9	16.0
Axis Bank	Neutral	1172	1225	4	80.7	85.5	98.6	14.9	6.0	15.4	13.7	11.9	2.1	1.8	16.2	16.2
Bandhan Bank	Neutral	211	220	4	13.8	24.4	28.6	1.6	76	17.0	8.6	7.4	1.4	1.2	17.1	17.5
DCB Bank	Buy	117	175	49	17.1	19.3	24.2	14.6	12.8	25.1	6.1	4.9	0.7	0.6	12.0	13.4
Equitas Small Fin.	Buy	73	100	37	7.1	5.6	8.9	46.6	-20.8	58.7	12.9	8.1	1.3	1.1	10.3	14.8
Federal Bank	Buy	187	230	23	16.3	16.9	20.5	14.5	3.5	20.9	11.0	9.1	1.4	1.2	13.4	14.3
HDFC Bank	Buy	1650	2000	21	80.0	89.3	100.7	1.0	11.5	12.8	18.5	16.4	2.5	2.3	14.5	14.6
ICICI Bank	Buy	1223	1400	14	58.4	63.6	72.0	27.5	9.0	13.1	19.2	17.0	3.1	2.7	17.6	17.2
IDFC First Bk	Neutral	72	83	15	4.3	4.2	6.0	13.8	-2.1	41.0	17.1	12.1	1.5	1.3	8.9	11.4
IndusInd	Buy	1348	1700	26	115.5	113.9	140.4	20.3	-1.4	23.3	11.8	9.6	1.5	1.3	13.3	14.5
Kotak Mah. Bk	Neutral	1883	1800	-4	91.6	94.6	110.5	21.9	3.2	16.8	19.9 9.7	17.0	2.5	2.2	13.7	13.9
RBL Bank SBI Cards	Neutral Neutral	204 734	250 850	22 16	19.3 25.4	21.0 27.6	29.6 37.2	31.1 6.2	8.8	40.7 34.8	26.6	6.9 19.8	0.8 4.8	0.7 4.0	8.3 19.8	11.0 22.1
	Neutrai	734	630	10	25.4	27.0	37.2	27.0	9.3	15.8	19.2	17.6	2.9	2.5	15.1	14.5
Aggregate Banks - PSU								27.0	3.3	15.0	15.2	17.0	2.5	2.5	15.1	14.5
BOB	Dun/	242	290	20	34.4	37.6	41.3	26.1	9.4	9.9	6.4	5.9	1.0	0.9	16.9	16.3
Canara Bank	Buy	104	133	28	16.0	17.8	19.4	37.3	10.9	8.9	5.8	5.9	1.0	0.9	19.2	18.2
Indian Bank	Buy	524	670	28	62.2	75.9	83.3	46.7	22.0	9.8	6.9	6.3	1.1	1.0	18.1	17.3
Punjab Natl.Bank	Neutral	105	135	29	7.5	13.0	15.3	228.8	74.2	17.3	8.0	6.9	1.0	0.9	13.8	14.4
SBI	Buy	800	1015	27	75.2	87.7	100.9	20.6	17	15.1	9.1	7.9	1.5	1.3	18.5	17.9
Union Bank (I)	Buy	114	165	45	18.9	20.5	23.5	52.9	8	14.7	5.6	4.9	0.8	0.7	16.0	16.1
Aggregate	Duy	114	103	40	10.5	20.3	۷.,	34.0	19	14.7	9	7.8	1.4	1.3	15.4	16.1
NBFCs								37.0	13	1-7	,	7.0	1.4	1.5	13.4	10.1
AAVAS Financiers	Neutral	1721	2070	20	62.0	74.4	90.4	14.0	20.0	21.4	23.1	19.0	3.1	2.7	14.5	15.2
Aditya Birla Cap	Buy	221	270	22	10.1	13.2	17.1	19.0	30.9	29.2	16.7	12.9	1.9	1.7	12.1	13.9
Angel One	Buy	2702	3500	30	135.9	185.2	214.8	26.4	36.3	16.0	14.6	12.6	3.7	3.1	33.7	26.9
	- w y	2,02	3300	50	100.0	100.2		20.7	50.5	-0.0	_−.∪	-2.0	٥.,	٠.1	55.7	_0.5



Company Bajaj Fin. BSE Cams Services Can Fin Homes Cholaman.Inv.&Fn CreditAccess	Reco Neutral Neutral Buy Neutral Buy Buy	(INR) 7300 4496 4514	TP (INR) 8600 4000	% Upside Downside	FY24	EPS (INR FY25E	FY26E	FY24	Gr. YoY FY25E	• •	FY25E	FY26E		3 (x) FY26E	ROE FY25E	• •
Bajaj Fin. BSE Cams Services Can Fin Homes Cholaman.Inv.&Fn	Neutral Neutral Buy Neutral Buy	7300 4496	8600			FIZJL	FIZUL	F124	FIZJL	FIZUL	FIZJL	FIZUL	FIZJL	FIZUL	FIZJL	
BSE Cams Services Can Fin Homes Cholaman.Inv.&Fn	Neutral Buy Neutral Buy	4496			233.7	273.2	363.5	22.8	16.9	33.1	26.7	20.1	4.7	3.9	19.6	21.3
Cams Services Can Fin Homes Cholaman.Inv.&Fn	Buy Neutral Buy			-11	57.0	85.2	96.2	275.5	49.4	13.0	52.8	46.7	16.7	15.1	31.6	32.2
Can Fin Homes Cholaman.Inv.&Fn	Neutral Buy	7317	5300	17	71.6	94.5	114.0	23.3	31.9	20.7	47.8	39.6	20.5	17.4	46.5	47.6
Cholaman.Inv.&Fn	Buy	867	960	11	56.4	63.5	72.8	20.8	12.6	14.7	13.7	11.9	2.3	1.9	17.9	17.5
		1502	1850	23	40.7	53.4	73.1	25.6	31.0	36.9	28.2	20.6	5.3	4.0	20.6	22.5
		1077	1420	32	90.7	81.2	97.9	74.5	-10.5	20.6	13.3	11.0	2.2	1.9	18.1	18.4
Fusion Micro	NA	NA	NA	J2	NA	NA	NA	, 1.5	NA	NA	NA	NA	NA	NA	NA	NA
Five-Star Business	Buy	805	1000	24	28.6	36.7	44.3	38.0	28.6	20.5	21.9	18.2	3.8	3.1	18.7	18.8
HDFC Life Insur.	Buy	724	900	24	7.3	8.5	9.5	15.3	16.3	12.4	85.3	75.9	2.8	2.4	17.2	16.6
Home First Fin.	Buy	1217	1355	11	34.5	42.4	52.6	33.2	22.8	24.1	28.7	23.1	4.4	3.7	16.4	17.5
ICICI Pru Life	Buy	742	930	25	5.9	6.9	8.9	5.0	17.3	28.8	106.9	83.0	2.1	1.8	19.5	19.9
ICICI Lombard	Buy	2068	2650	28	38.9	50.8	60.6	11.0	30.5	19.3	40.7	34.1	7.5	6.4	19.5	20.2
IIFL Finance	Buy	470	580	24	46.2	26.5	48.3	17.2	-42.7	82.3	17.7	9.7	1.6	1.4	9.6	14.9
360 ONE WAM	Buy	1058	1300	23	22.4	29.2	34.6	21.3	30.5	18.4	36.2	30.6	10.4	9.7	29.5	32.8
IndoStar	Buy	278	290	4	8.5	12.5	17.6	-48.5	47.3	40.2	22.2	15.8	1.1	1.1	5.1	7.1
L&T Finance	Buy	164	225	37	9.3	11.4	14.2	42.4	22.2	25.1	14.4	11.5	1.6	1.4	11.5	13.1
Life Insurance	Dun.	040	1200	37	642	70.2	76.2	11 0	0.1	0 E	12 E	12 5	0.7	0.7	11 [11 2
Corp.	Buy	949	1300	37	64.3	70.2	70.2	11.8	9.1	8.5	13.5	12.5	0.7	0.7	11.5	11.3
LIC Hsg Fin	Buy	620	830	34	86.6	89.2	93.3	64.8	3.0	4.6	6.9	6.6	1.0	0.9	14.7	13.8
MCX	Buy	6410	6700	5	16.3	109.3	142.2	-44.2	570.4	30.1	58.7	45.1	21.9	20.0	38.8	46.4
Manappuram Fin.	Buy	186	250	34	26.0	27.4	33.4	46.5	5.6	21.9	6.8	5.6	1.2	1.0	18.5	19.1
MAS Financial	Buy	294	360	22	15.1	16.9	21.7	23.3	11.6	29.0	17.4	13.5	2.1	1.9	14.5	14.7
Max Financial	Neutral	1187	1250	5	7.6	11.1	13.0	-17.8	46.5	17.5	107.2	91.2	2.2	1.8	19.1	19.4
M&M Fin.	Buy	284	395	39	14.3	20.7	28.3	-11.4	45.1	36.7	13.7	10.1	1.7	1.5	12.7	15.7
Muthoot Fin	Neutral	1945	1800	-7	100.9	126.7	145.3	16.6	25.6	14.7	15.3	13.4	2.8	2.4	19.3	19.1
Piramal Enterp.	Neutral	1080	1000	-7	-75.0	41.0	79.9	-200.1	LP	94.9	26.3	13.5	0.9	0.8	3.4	6.4
PNB Housing	Buy	975	1235	27	58.1	70.3	88.9	-6.3	21.1	26.5	13.9	11.0	1.5	1.3	11.5	13.0
Poonawalla Fincorp	Buy	381	460	21	13.4	16.8	21.3	73.3	25.5	26.8	22.6	17.8	3.2	2.7	14.8	16.4
PFC	Buy	468	560	20	43.5	49.9	55.0	-1.0	14.6	10.3	9.4	8.5	1.7	1.5	19.4	18.7
REC	Buy	538	630	17	53.2	60.5	69.3	26.8	13.6	14.7	8.9	7.8	1.8	1.5	21.3	20.9
Repco Home Fin	Neutral	498	580	17	63.1	68.9	74.3	33.3	9.2	7.9	7.2	6.7	0.9	0.8	13.9	13.2
Spandana																
Sphoorty	Buy	539	675	25	70.2	12.7	73.0	3,922.1	-81.9	474.7	42.4	7.4	1.0	0.9	2.5	13.0
Shriram Finance	Buy	3342	4100	23	191.3	224.9	272.7	19.8	17.5	21.3	14.9	12.3	2.3	2.0	16.3	17.2
SBI Life Insurance	Buy	1735	2200	27	18.9	24.5	25.0	9.9	29.3	1.9	70.8	69.5	2.4	2.0	22.0	20.5
Star Health Insu	Buy	548	720	31	14.4	18.4	24.3	35.8	27.3	32.3	29.8	22.5	4.2	3.5	15.0	16.9
Aggregate								5.8	17.5	23.3	18.8	16.0	2.9	2.5	15.3	15.5
Chemicals																
Alkyl Amines	Neutral	2279	2305	1	29.1	41.5	56.9	-34.9	42.7	37.2	54.9	40.0	8.3	7.3	15.9	19.4
Atul	Buy	7895	9955	26	103.4	172.6	222.4	-38.8	66.8	28.9	45.7	35.5	4.2	3.8	9.5	11.3
Clean Science	Neutral	1568	1580	1	23.0	26.6	36.0	-17.3	15.7	35.3	59.0	43.6	11.5	9.4	21.3	23.7
Deepak Nitrite	Neutral	2829	3005	6	55.1	73.8	80.6	-11.7	33.9	9.1	38.3	35.1	6.8	5.8	19.2	17.9
Fine Organic	Sell	5082	4250	-16	120.0	118.8	119.0	-37.7	-1.0	0.2	42.8	42.7	7.1	6.2	18.0	15.4
Galaxy Surfact.	Buy	2936	3750	28	85.0	97.7	115.0	-20.9	14.9	17.7	30.1	25.5	4.3	3.8	15.0	15.8
Navin Fluorine	Neutral	3386	3355	-1	46.1	60.4	85.3	-39.1	31.1	41.2	56.0	39.7	6.5	5.8	12.0	15.4
NOCIL	Neutral	290	315	8	7.9	9.4	11.7	-11.7	19.2	24.9	30.9	24.8	2.7	2.5	9.0	10.6
PI Inds.	Buy	4523	5470	21	110.6	112.5	136.9	36.8	1.7	21.7	40.2	33.1	6.7	5.6	18.0	18.5
SRF	Neutral	2348	2240	-5	47.5	51.1	73.8	-37.7	7.7	44.3	45.9	31.8	5.6	4.9	12.7	16.4
Tata Chemicals	Neutral	1184	1070	-10	36.1	30.2	49.2	-60.5	-16.3	62.7	39.2	24.1	1.3	1.3	3.4	5.4
Vinati Organics	Buy	1967	2500	27	31.2	42.7	50.9	-22.8	36.8	19.2	46.1	38.7	7.3	6.3	16.8	17.5
Aggregate								-26.4	28.2	20.2	55.5	43.3	6.7	6.0	12.1	13.8
Capital Goods																
ABB India	Buy	8549	9500	11	58.9	97.0	114.2	81.9	64.7	17.8	88.1	74.9	23.1	18.0	29.8	27.0
Bharat Electronics	Buy	286	360	26	5.5	6.7	8.2	33.7	21.0	22.7	43.0	35.0	10.3	8.2	24.0	23.5



		CMP	TP	% Upside		EPS (INR)	EPS	Gr. YoY	(%)	P/E	(x)	P/E	3 (x)	ROE (%)	
Company	Reco	(INR)	(INR)	Downside	FY24	FY25E	FY26E	FY24	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26
Cummins India	Buy	3612	4300	19	60.0	74.2	89.0	33.4	23.7	19.9	48.7	40.6	14.4	12.6	31.3	33.1
Hitachi Energy	Neutral	15925	12800	-20	38.6	75.4	149.9	74.4	95.3	98.7	211.1	106.2	40.2	29.2	19.0	27.5
Kalpataru Proj.	Buy	1320	1500	14	32.6	49.3	69.6	8.3	51.3	41.1	26.8	19.0	3.4	2.9	13.2	16.4
KEC International	Neutral	999	950	-5	13.5	25.7	42.5	97.0	90.3	65.5	38.9	23.5	4.7	4.1	13.9	18.8
Kirloskar Oil	Buy	1171	1540	32	25.0	36.1	46.2	33.8	44.4	28.2	32.5	25.3	5.6	4.8	18.6	20.6
Larsen & Toubro	Buy	3483	4250	22	94.5	108.0	135.7	24.5	14.3	25.7	32.3	25.7	4.9	4.3	16.1	17.8
Siemens	Buy	7748	8400	8	55.1	73.4	87.5	55.5	33.3	19.2	105.5	88.5	18.4	15.9	18.6	19.3
Thermax	Neutral	5161	4950	-4	52.2	66.0	83.6	30.3	26.5	26.7	78.2	61.7	11.6	10.0	15.7	17.4
Triveni Turbine	Buy	797	830	4	8.5	11.0	14.3	39.8	30.5	29.4	72.1	55.7	20.9	16.5	32.3	33.0
Zen Technologies	Buy	1900	1900	0	15.1	28.8	41.8	218.8	90.9	45.0	65.9	45.5	23.0	15.3	42.2	40.3
Aggregate	,							32.3	23.9	26.1	60.7	49.0	10.0	8.6	16.5	17.5
Cement																
Ambuja Cem.	Buy	585	740	26	13.9	9.5	15.2	-2.2	-31.8	59.9	61.7	38.6	2.6	2.5	4.9	6.7
ACC	Buy	2314	3170	37	99.3	87.9	116.2	88.7	-11.5	32.1	26.3	19.9	2.5	2.2	9.9	11.8
Birla Corp.	Buy	1214	1650	36	54.0	31.6	64.4	1,052.2	-41.5	103.8		18.9	1.4	1.3	3.6	7.1
Dalmia Bhar.	Buy	1872	2390	28	40.8	52.5	69.5	11.5	28.7	32.5	35.7	26.9	2.1	1.9	5.9	7.4
Grasim Inds.	Buy	2726	3230	19	95.6	89.5	103.6	-2.9	-6.4	15.7	30.4	26.3	3.3	3.2	0.9	2.5
India Cem	Sell	362	310	-14	-7.6	-12.4	-1.3	-49.9	Loss	Loss	NM	NM	2.2	2.2	-7.3	-0.8
J K Cements	Buy	4239	5270	24	102.7	96.3	136.3	86.2	-6.3	41.6	44.0	31.1	5.5	4.9	13.2	16.6
JK Lakshmi Ce	Buy	826	970	18	39.6	26.8	37.2	29.9	-32.2	38.8	30.8	22.2	2.8	2.6	9.5	12.1
Ramco Cem	Neutral	861	860	0	16.7	11.9	22.2	15.0	-28.8	86.8	72.3	38.7	2.8	2.6	3.9	6.9
Shree Cem	Neutral	24314	26580	9	684.2	449.3	510.4	110.3	-34.3	13.6	54.1	47.6	4.1	3.8	7.7	8.3
Ultratech	Buy	11421	13600	19	244.5	250.8	336.6	39.4	2.6	34.2	45.5	33.9	5.0	4.2	11.5	13.5
Aggregate			10000					30.3	-10.3	35.1	38.0	42.4	3.8	3.4	10.0	8.1
Consumer																
Asian Paints	Neutral	3038	3150	4	57.9	55.3	61.8	30.9	-4.6	11.8	55.0	49.2	14.6	13.3	27.4	28.3
Britannia	Neutral	5978	6100	2	88.7	101.2	113.9	10.1	14.1	12.5	59.1	52.5	31.6	26.5	57.4	54.9
Colgate	Neutral	3689	3550	-4	49.2	56.9	63.4	26.8	15.7	11.3	64.8	58.2	45.6	39.2	76.0	72.4
Dabur	Buy	571	725	27	10.6	10.9	12.6	9.2	3.3	15.3	52.2	45.3	9.4	8.7	18.8	20.0
Emami	Buy	731	950	30	18.0	20.4	23.1	17.0	13.3	13.1	35.7	31.6	11.5	10.0	34.1	33.9
Godrej Cons.	Buy	1316	1650	25	19.3	21.7	26.7	13.2	12.1	23.1	60.8	49.4	9.8	8.9	16.8	18.9
HUL	Buy	2781	3400	22	43.7	46.3	52.3	0.7	6.0	12.9	60.0	53.2	12.6	12.3	21.1	23.4
ITC	Buy	488	585	20	16.4	17.0	18.6	9.0	3.8	9.1	28.7	26.3	7.8	7.4	27.9	28.9
Indigo Paints	Buy	1482	1750	18	31.0	30.6	37.3	27.5	-1.2	21.9	48.4	39.7	6.9	6.1	15.2	16.3
Jyothy Lab	Neutral	528	575	9	9.8	11.1	12.4	54.8	12.8	12.3	47.7	42.5	10.1	9.1	21.8	22.6
Marico	Buy	686	780	14	11.5	12.6	13.9	13.7	9.5	10.8	54.5	49.2	22.3	21.3	41.6	44.2
Nestle	Neutral	2512	2650	5	41.0	36.2	40.2	62.5	-11.7	10.9	69.3	62.5	60.3	50.8	95.0	88.3
Page Inds	Neutral	45344	40000	-12	510.3	573.3	701.4	-0.4	12.3	22.3	79.1	64.6	29.0	25.0	36.7	38.6
Pidilite Ind.	Neutral	3111	3200	3	35.9	42.3	49.4	42.2	17.9	16.7	73.6	63.0	16.6	14.9	23.9	24.9
P&G Hygiene	Neutral	16623	17000	2	220.3	260.2	296.4	15.1	18.2	13.9	63.9	56.1	57.2	47.5	98.4	92.6
Tata Consumer	Buy	1113	1380	24	14.3	15.0	20.1	26.1	4.7	34.0	74.1	55.3	5.0	4.7	8.2	9.5
United Brew	Sell	2088	1950	-7	15.5	22.8	32.2	24.7	46.4	41.7	91.8	64.8	12.3	11.1	13.9	18.0
United Spirits	Neutral	1520	1550	2	18.1	18.4	20.8	42.7	1.6	13.2	82.6	73.0	13.3	11.3	16.1	15.4
Varun Beverages	Buy	592	730	23	6.3	8.0	10.2	37.3	26.8	27.1	73.8	58.0	20.9	15.8	32.3	30.9
Aggregate	Suy	332	, 30		0.5	0.0	10.2	15.0	4.7	12.8	52.1	49.8	13.2		25.4	24.7
Consumer								15.0	***	12.0	52.1	.5.0	10.2		23.4	/
Durables																
Havells India	Neutral	1938	1920	-1	20.3	25.8	31.4	18.5	27.4	21.4	75.0	61.8	14.3	12.4	19.0	20.1
KEI Industries	Buy	4578	5300	16	64.4	78.1	96.8	21.7	21.2	24.0	58.6	47.3	10.8	8.9	18.5	18.9
Polycab India	Buy	7447	8550	15	118.8	130.1	156.6	40.0	9.6	20.4	57.2	47.5	11.5	9.7	20.2	20.4
R R Kabel	Buy	1719	2130	24	26.4	32.0	45.5	57.0	21.2	42.1	53.7	37.8	9.2	7.7	18.3	22.2
Voltas	Buy	1794	2100	17	7.2	27.1	34.8	-36.8	274.0	28.7	66.3	51.5	8.9	7.8	13.5	15.2
Aggregate	· ,					.=		23.2	32.6	23.9	84.4	63.6	13.3	11.4	15.8	18.0
EMS																
Amber Enterp.	Buy	5024	5500	9	40.1	68.1	105.1	-14.0	69.6	54.3	73.8	47.8	7.4	6.4	10.5	14.3
p.	1					JU. 1	_00.1		-5.0		. 0.0			.	_0.0	



		CMP	TP	0/ 11==:-		EPS (INR	`	EDC	C: V-V	/o/\	D/I	- ()	D/I	2 (-1)	DOI:	- (0/)
Company	Paca			% Upside Downside		FY25E	FY26E	FY24	Gr. YoY	• •	FY25E	EV26E		3 (x)		EV26E
Company Avalon Toch	Reco	(INR) 626	(INR) 690	10	4.3	6.7	15.1	-53.0	58.3	123.3		41.6	7.0	6.0	7.8	15.4
Avalon Tech	Buy										50.1		5.4	4.6		
Cyient DLM	Buy	695 2475	880 2400	27	7.7 32.4	13.9 40.0	22.0 53.1	92.9 46.6	79.6 23.2	58.8	61.9	31.6 46.6			11.4	15.8 17.6
Data Pattern	Neutral			-3			168.3	43.3	85.4	32.8 47.6		90.0	9.0	7.6 27.1	15.6	35.3
Dixon Tech.	Buy	15146	16000	6	61.5	114.0					132.9				33.6	
Kaynes Tech	Buy	5580	6400	15 27	28.7 6.1	53.4 9.0	94.2 15.0	75.3 -9.3	86.2 46.3	76.3 67.7	104.5 46.6	59.2	12.6	10.4	12.8	19.2
Syrma SGS Tech.	Buy	417	530	21	0.1	9.0	15.0					27.8	4.2	3.7	9.5	14.3
Aggregate								27.6	67.9	56.5	159.1	94.8	15.9	13.7	10.0	14.5
Healthcare Alembic Phar	Neutral	1172	1150	-2	31.5	37.4	41.2	42 O	10 0	10.2	31.4	20.4	4.2	2.0	14.2	12.0
		6179	1150 6072	-2 -2	159.7	187.8	204.3	43.9 50.6	18.8 17.6	10.3	32.9	28.4 30.2	6.1	3.8 5.3	20.1	13.9 18.8
Alkem Lab	Neutral											38.2				
Apalla Haspitals	Buy	3348	3790 8330	13	62.3 62.4	75.8 94.4	87.8 125.5	26.6 29.6	21.7	15.7 33.0	74.0	55.7	9.9	8.3	24.5	23.7 19.9
Apollo Hospitals	Buy	6987		19					51.2				11.8	9.8	17.9	
Aurobindo	Neutral	1495	1480	-1	56.0	66.3	73.8	46.1	18.3	11.3	22.5	20.3	2.6	2.3	12.3	12.2
Biocon	Neutral	346	340	-2	1.8	4.4	9.2	-71.1	144.4	109.8	78.5	37.4	2.0	1.9	2.6	5.3
Cipla	Buy	1595	1940	22	52.5	58.7	65.6	39.0	11.9	11.7	27.2	24.3	4.2	3.6	15.4	14.9
Divis Lab	Neutral	6141	5300	-14	60.0	77.7	95.1	-7.5	29.6	22.4	79.0	64.5	10.9	9.7	14.4	15.9
Dr Reddy's	Neutral	6601	6930	5	317.1	353.8	389.0	29.6	11.6	9.9	18.7	17.0	3.3	2.8	19.1	17.7
ERIS Lifescience	Neutral	1386	1220	-12	29.2	30.4	42.0	5.2	4.0	38.0	45.5	33.0	6.5	5.6	15.2	18.2
Gland Pharma	Buy	1698	2170	28	47.6	53.4	67.0	-5.6	12.1	25.6	31.8	25.3	2.9	2.6	9.6	10.9
Glenmark	Buy	1793	1930	8	2.5	47.5	59.2	-88.0	1,811.9		37.8	30.3	5.6	4.7	15.8	16.8
GSK Pharma	Neutral	2783	2720	-2	43.3	48.1	53.4	20.5	11.1	11.1	57.9	52.1	22.2	18.4	38.3	35.3
Global Health	Buy	1026	1263	23	17.8	19.3	24.8	46.7	8.2	29.0	53.3	41.3	8.3	7.1	16.6	18.5
Granules India	Buy	603	645	7	17.4	22.2	29.4	-19.5	27.7	32.8	27.2	20.5	3.9	3.3	15.4	17.5
IPCA Labs	Neutral	1656	1610	-3	20.8	33.5	43.0	0.0	61.3	28.2	49.4	38.5	6.0	5.3	12.7	14.5
Laurus Labs	Buy	474	540	14	3.0	6.7	11.9	-79.6	121.9	78.3	70.8	39.7	5.8	5.1	8.4	13.7
Lupin	Neutral	2224	2060	-7	41.5	59.2	69.8	382.6	42.5	17.8	37.6	31.9	6.0	5.1	17.3	17.4
Mankind Pharma	Buy	2794	3000	7	47.8	54.5	62.4	38.5	14.1	14.6	51.3	44.7	10.2	8.7	21.4	20.9
Max Healthcare	Buy	940	1238	32	13.7	15.6	19.1	18.6	13.9	22.4	60.1	49.1	8.4	7.2	15.1	15.8
Piramal Pharma	Buy	221	280	26	0.4	2.6	5.3	-170.2	509.3	107.2	85.8	41.4	3.2	2.9	4.2	8.2
Sun Pharma	Buy	1902	2220	17	41.4	49.2	57.9	15.8	18.6	17.8	38.7	32.8	6.2	5.3	17.2	17.4
Torrent Pharma	Neutral	3498	3430	-2	47.1	63.4	82.0	26.7	34.6	29.3	55.2	42.7	7.2	5.9	28.5	30.5
Zydus Lifesciences	Neutral	1066	1140	7	37.6	43.9	47.3	68.0	16.5	7.9	24.3	22.5	4.2	3.7	19.6	17.4
Aggregate								24.8	24.0	18.3	46.9	37.9	6.5	5.6	13.7	14.8
Infrastructure																
G R Infraproject	Buy	1618	2050	27	73.0	79.2	99.9	-17.2	8.5	26.2	20.4	16.2	2.0	1.8	10.1	11.5
IRB Infra	Neutral	59	62	4	1.0	1.6	2.1	-15.9	58.6	30.8	37.3	28.5	2.5	2.3	6.8	8.4
KNR Constructions	Buy	319	410	29	15.2	14.6	18.9	3.3	-4.4	29.7	21.9	16.9	2.4	2.1	11.9	13.5
Aggregate											34.7	28.3	2.5	2.3	7.2	8.2
Logistics																
Adani Ports	Buy	1408	1880	34	41.3	51.2	61.1	16.5	24.2	19.2	27.5	23.0	4.8	4.1	19.1	19.3
Blue Dart Express	Buy	8472	9900	17	121.6	137.1	223.5	-21.2	12.7	63.0	61.8	37.9	12.4	10.0	21.3	29.2
Concor	Buy	894	1150	29	20.3	22.3	32.6	5.8	9.9	46.1	40.0	27.4	4.3	4.0	11.2	15.2
JSW Infra	Buy	321	410	28	5.8	6.5	9.3	6.8	11.7	44.3	49.6	34.4	7.5	6.4	15.9	20.0
Mahindra Logistics	Neutral	501	530	6	-8.2	6.6	19.1	-322.8	LP	188.9	75.6	26.2	6.9	5.6	9.1	23.1
Transport Corp.	Buy	1037	1290	24	45.8	52.6	64.5	10.1	14.8	22.6	19.7	16.1	3.4	2.8	18.2	18.8
TCI Express	Buy	1039	1370	32	34.4	32.8	43.5	-5.4	-4.5	32.6	31.6	23.9	5.0	4.3	16.7	19.2
VRL Logistics	Buy	577	670	16	10.1	12.7	23.4	-46.1	25.7	83.6	45.3	24.7	5.2	4.7	11.6	20.1
Aggregate											38.4	31.5	5.9	5.1	15.5	16.3
Media																
PVR Inox	Neutral	1620	1590	-2	11.7	3.5	29.1	-152.3	-69.6	722.2	457.5	55.6	2.2	2.1	0.5	3.8
Sun TV	Neutral	784	860	10	47.6	47.1	50.2	12.0	-1.0	6.5	16.6	15.6	2.8	2.6	16.8	16.5
Zee Ent.	Neutral	130	155	19	4.5	7.2	10.3	-4.9	59.9	42.6	18.0	12.6	1.1	1.0	6.2	8.4
Aggregate								16.7	6.7	25.8	24.5	22.9	2.1	2.0	8.5	8.7
Metals																
Coal India	Buy	493	590	20	60.7	61.2	67.4	17.8	0.9	10.1	8.1	7.3	3.0	2.5	37.3	34.2





		CMP	TP	% Upside		EPS (INR)	EPS	Gr. YoY	(%)	p/F	(x)	p/F	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside		FY25E	FY26E	FY24	FY25E					• •		• •
Hindalco	Buy	747	880	18	45.6	63.0	63.1	0.8	38.0	0.1	11.9	11.8	1.8	1.6	16.2	14.2
Hind. Zinc	Neutral	504	570	13	18.4	22.5	30.6	-26.2	22.3	36.1	22.4	16.5	10.9	7.8	54.5	54.9
JSPL	Buy	1006	1200	19	58.4	54.8	95.5	60.4	-6.2	74.3	18.3	10.5	2.0	1.7	11.7	17.9
JSW Steel	Buy	1011	1200	19	36.8	32.6	67.8	148.7	-11.5	108.1	31.1	14.9	2.9	2.5	9.8	17.9
Nalco	Neutral	223	220	-1	9.1	12.9	13.9	16.3	42.2	7.8	17.2	16.0	2.5	2.3	15.6	15.0
NMDC	Buy	233	290	24	19.7	24.8	27.1	18.0	25.8	9.2	9.4	8.6	2.2	1.9	25.8	23.8
SAIL	Neutral	134	140	4	2.6	4.1	10.4	-43.8	58	150.6	32.4	12.9	1.0	0.9	3.0	7.2
Tata Steel	Neutral	161	180	12	2.7	5.9	12.4	-61.8	119	108.7	27.1	13.0	2.3	2.1	8.5	17.0
Vedanta	Neutral	497	550	11	13.3	36.2	44.1	-53.1	173	21.7	13.7	11.3	5.2	4.2	40.6	41.2
Aggregate								0.1	22.9	32.1	18.0	14.7	2.9	2.6	15.9	17.6
Oil & Gas																
Aegis Logistics	Neutral	683	810	19	16.2	17.5	21.7	10.8	7.9	24.2	39.0	31.4	5.6	5.0	15.0	16.8
BPCL	Neutral	338	340	1	63.3	32.6	35.5	1,271.9	-48.5	8.9	10.4	9.5	1.7	1.6	17.6	17.6
Castrol India	Buy	228	300	32	8.7	9.4	9.6	6.0	7.4	2.7	24.3	23.6	10.0	9.4	42.4	41.1
GAIL	Buy	230	290	26	13.7	15.3	17.3	70.1	11.5	13.2	15.0	13.3	2.1	1.9	15.0	15.5
Gujarat Gas	Buy	600	730	22	16.0	19.0	22.7	-27.8	19.0	19.2	31.5	26.4	4.8	4.3	16.1	17.2
Gujarat St. Pet.	Neutral	411	472	15	22.8	13.1	12.1	35.9	-42.4	-7.7	31.3	33.9	2.1	2.1	7.0	6.2
HPCL	Buy	395	510	29	75.2	30.2	47.1	-329.4	-59.9	56.2	13.1	8.4	1.6	1.4	13.0	18.2
IOC	Buy	163	225	38	29.5	10.5	13.7	344.7	-64.4	30.9	15.6	11.9	1.2	1.1	7.7	9.5
IGL	Sell	540	466	-14	25.0	23.3	26.2	21.0	-6.6	12.5	23.2	20.6	3.9	3.4	17.9	17.8
Mahanagar Gas	Buy	1835	2430	32	132.3	129.4	137.0	65.4	-2.2	5.9	14.2	13.4	3.1	2.7	23.1	21.4
MRPL	Sell	175	150	-14	20.5	8.7	15.6	36.6	-57.7	80.0	20.1	11.2	2.1	1.8	11.0	17.6
Oil India	Buy	584	720	23	48.7	46.2	51.3	16.2	-5.0	11.0	12.6	11.4	1.9	1.7	16.1	16.0
ONGC	Buy	293	365	25	46.3	45.0	52.8	44.9	-2.8	17.2	6.5	5.5	1.0	0.9	15.9	16.5
PLNG	Neutral	355	394	11	23.6	25.3	30.5	9.1	7.3	20.7	14.0	11.6	2.8	2.5	21.1	22.6
Reliance Ind.	Buy	2742	3409	24	102.9	102.5	134.3	4.4	-0.4	31.0	26.8	20.4	2.1	1.9	8.4	10.1
Aggregate								80.0	-21.7	24.0	13.1	16.7	2.0	1.8	15.0	10.8
Real Estate		4205	4620	2.5	22.4	27.4	42.0	00.6	67.0	42.2	240	20.0	1	- 4	40.0	40.0
Brigade Enterpr.	Buy	1295	1630	26	22.1	37.1	42.0	82.6	67.9	13.2	34.9	30.8	6.1	5.1	18.9	18.0
DLF	Neutral	847	850	0	11.0	16.6	17.0	-3.5	50.5	2.4	51.2	50.0	3.5	3.3	10.0	9.4
Godrej Propert.	Buy	3012 391	3725	24	26.9 -9.2	52.0 13.3	34.4 42.1	20.3	93.4 LP	-33.8	57.9 29.5	87.5	7.3	6.8 2.7	13.5	8.0 33.6
Kolte Patil Dev.	Buy		620	58	53.0	50.5		1.2	-4.6	217.1	38.0	9.3	3.7	3.9	13.1	
Oberoi Realty	Neutral	1919	1700	-11			71.0			40.5			4.5		12.6	15.6
Macrotech Devel. Mahindra	Buy	1169	1770	51	16.9	23.4	35.3	6.0	38.3	51.0	49.9	33.1	5.7	4.9	12.1	16.0
Lifespace	Neutral	507	600	18	6.3	6.3	6.9	111.6	0.5	8.9	80.0	73.4	4.1	3.9	5.2	5.4
SignatureGlobal	Buy	1490	2000	34	1.2	47.4	69.2	-129.1	3,931.0	46.1	31.5	21.5	16.2	9.2	69.4	54.7
Sunteck Realty	Buy	556	745	34	4.8	16.2	23.2	4,699.7	,	43.1	34.3	23.9	2.4	2.2	7.4	9.7
Sobha	Buy	1704	2250	32	5.1	35.2	74.2	-52.9		110.5		23.0	5.8	4.7	12.7	22.6
Prestige Estates	Buy	1855	2150	16	19.0	19.9	26.2	-1.5	5.0	31.9	93.3	70.7	5.8	5.4	6.4	7.9
Phoenix Mills	Neutral	1629	1650	1	30.8	30.3	41.6	50.6	-1.4	36.9	53.7	39.2	5.6	4.9	10.9	13.3
Aggregate								18.3	44.6	23.8		51.4	6.2	5.6	8.3	10.8
Retail																
Avenue Supermarts	Buy	4572	5300	16	39.0	44.3	55.2	6.2	13.7	24.6	103.1	82.8	13.8	11.8	14.3	15.4
Aditya Birla Fashion	Neutral	340	380	12	-7.4	-6.6	-6.2	955.4	Loss	Loss	NM	NM	8.5	10.1	-15.2	-16.8
Bata India	Neutral	1406	1520	8	22.8	26.4	33.6	-9.3	16.1	27.0	53.2	41.9	10.1	9.0	20.5	22.8
Barbeque-Nation	Neutral	683	700	2	-2.9	-2.4	1.2	-172.8	Loss	LP	NM	548.1	7.0	6.9	-2.4	1.3
Campus Activewe.	Buy	316	390	24	2.9	4.3	5.6	-23.6	46.8	30.8	73.6	56.3	12.3	10.1	16.8	18.0
Devyani Intl.	Buy	182	220	21	0.8	0.8	1.9	-66.5	-2.3		241.8	97.2	31.3	33.1	10.3	33.1
Jubilant Food.	Neutral	630	625	-1	3.9	5.3	8.0	-32.9	34.8	50.4			18.0	16.9	15.2	21.4
Kalyan Jewellers	Buy	721	850	18	5.8	8.4	11.4	29.9	44.9	35.4	85.8	63.3	15.4	13.1	19.2	22.3
Metro Brands	Buy	1225	1525	24	12.7	14.8	18.1	-5.2	16.3	21.9	82.7	67.8	14.8	12.5	19.9	20.5
Relaxo Footwear	Neutral	797	850	7	8.1	9.4	11.8	29.8	16.7	25.4	84.8	67.6	9.1	8.3	11.2	



-		CMP	TP	% Upside		EPS (INR)	EPS	Gr. YoY	(%)	P/I	E (x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside		FY25E	FY26E	FY24		FY26E						
Restaurant Brands		107	140	31	-4.8	-3.2	-0.8	-2.5	Loss	Loss	NM	NM	11.3	12.2	-28.7	-8.2
Sapphire Foods	Buy	371	415	12	1.6	1.4	3.4	-52.5	-15.8	147.9	270.2	109.0	8.5	7.9	3.2	7.5
Shoppers Stop	Neutral	773	900	16	5.5	7.0	10.2	-50.2	26.7	46.4	110.9	75.8	16.1	12.6	21.2	24.6
Senco Gold	Buy	1391	1700	22	23.3	31.3	37.4	1.6	34.4	19.5	44.4	37.2	6.8	5.8	16.4	16.8
Titan Company	Buy	3475	4300	24	39.3	45.5	56.4	6.8	15.9	23.9	76.4	61.6	25.3	19.6	37.5	35.9
Trent	Buy	8239	8760	6	29.2	54.3	73.2	162.5	86.0	34.7	151.6	112.6	45.6	31.8	38.4	35.6
V-Mart Retail	Neutral	4475	4670	4	-53.5	-3.0	35.7	1,132.9	Loss	LP	NM	125.2	10.9	10.0	NM	8.4
Vedant Fashions	Neutral	1323	1400	6	17.1	18.5	22.7	-3.5	8.6	22.7	71.4	58.2	18.1	15.8	26.2	26.3
Westlife Foodworld	Neutral	881	825	-6	4.4	3.0	7.7	-38.0	-32.6		294.4		17.6	17.5	6.8	15.3
Aggregate								-1.5	33.7	35.4	143.1	107.0	21.5	18.6	15.1	17.4
Technology																
Cyient	Buy	1852	2300	24	66.9	69.9	85.8	27.7	4.6	22.7	26.5	21.6	4.5	4.1	16.4	18.8
HCL Tech.	Buy	1840	2200	20	57.9	62.2	70.0	5.6	7.5	12.6	29.6	26.3	7.5	7.6	25.3	28.9
Infosys	Buy	1935	2200	14	63.3	64.0	72.2	10.0	1.0	12.8	30.3	26.8	9.1	9.1	30.1	33.9
LTI Mindtree	Buy	6412	7400	15	154.8	166.0	194.2	2.0	7.2	16.9	38.6	33.0	8.3	7.3	22.9	23.4
L&T Technology	Buy	5229	6600	26	123.0	129.3	152.5	11.3	5.1	17.9	40.4	34.3	9.1	7.8	24.1	24.4
Mphasis	Neutral	2876	3000	4	81.8	92.1	103.8	-6.0	12.6	12.7	31.2	27.7	5.7	5.3	19.2	20.0
Coforge	Buy	7383	8100	10	133.2	150.0	193.9	2.0	12.6	29.2	49.2	38.1	11.5	10.0	24.3	27.6
Persistent Sys	Buy	5466	6300	15	75.1	89.7	115.4	20.1	19.5	28.6	60.9	47.4	14.4	12.2	25.7	28.1
TCS	Buy	4151	5400	30	126.3	141.0	156.8	9.5	11.7	11.2	29.4	26.5	15.8	14.7	54.8	57.4
Tech Mah	Neutral	1646	1600	-3	41.1	44.0	63.2	-28.2	7.1	43.7	37.4	26.0	5.3	5.2	14.5	20.2
Wipro	Neutral	529	500	-5	20.4	22.1	24.4	-1.5	8.5	10.4	23.9	21.7	3.8	3.7	15.7	17.3
Zensar Tech	Neutral	696	770	11	29.1	27.3	31.3	102.7	-6.4	14.8	25.5	22.2	3.9	3.5	16.5	16.8
Aggregate	Neutrai	030	770	11	23.1	27.5	31.3	3.8	9.5	13.3	33.9	31.0	9.5	9.3	28.0	29.9
Telecom								3.0	J. J	13.3	33.3	31.0	J. J	J. J	20.0	23.3
Bharti Airtel	Buy	1687	2000	19	19.7	30.8	46.7	36.7	56.9	51.3	54.7	36.2	10.4	8.0	20.6	27.1
Indus Towers	Neutral	379	395	4	22.4	33.7	29.0	151.1	50.5	-14.1	11.2	13.1	3.1	2.5	29.5	20.8
Vodafone Idea	recution	9	333	-	-11.1	-9.8	-9.3	9.3	Loss	Loss	NM	NM	-0.3	-0.2	NM	NM
Tata Comm	Neutral	1963	1950	-1	42.3	46.9	66.9	-30.0	11.1	42.5	41.8	29.3	20.7	13.7	59.6	56
Aggregate								Loss	Loss	LP	-88	-3,974		71.1	####	-1.8
Utilities																
Indian Energy										400						
Exchange	Neutral	204	226	11	3.8	4.1	4.9	16.7	7.6	19.2	49.6	41.6	16.1	13.5	35.3	35.3
JSW Energy	Buy	707	917	30	10.5	17.9	20.8	24.2	70.1	16.5	39.5	33.9	5.0	4.4	13.3	13.8
NTPC	Neutral	422	450	7	22.0	23.6	26.4	24.6	7.2	12.1	17.9	16.0	2.4	2.2	13.7	14.2
Power Grid Corpn	Buy	330	425	29	16.7	18.4	19.2	1.0	9.6	4.7	18.0	17.2	3.4	3.2	19.1	19.1
Tata Power Co.	Buy	461	551	20	12.8	15.7	18.6	7.5	22.4	18.8	29.4	24.8	4.0	3.6	14.5	15
Aggregate								13.2	12.1	10.5	23	21	3.3	3.1	14.3	14.8
Others																
APL Apollo Tubes	Buy	1572	1860	18	26.4	28.4	45.7	14.1	7.5	61.0	55.4	34.4	10.3	8.2	20.1	26.5
Cello World	Buy	883	1150	30	15.6	18.3	23.0	24.4	17.4	25.8	48.3	38.4	12.3	9.4	25.5	24.5
Coromandel Intl	Buy	1640	1810	10	55.8	54.8	72.1	-18.5	-1.7	31.5	29.9	22.8	4.5	3.9	16.1	18.5
Dreamfolks Services	Buy	460	720	57	12.5	16.6	22.1	-6.2	32.5	33.0	27.7	20.8	7.4	5.4	32.2	31.1
EPL	Buy	264	310	18	8.2	10.4	14.4	13.5	27.7	38.0	25.2	18.3	3.7	3.3	15.2	18.9
Gravita India	Buy	2466	2900	18	34.6	43.7	60.4	18.9	26.2	38.1	56.4	40.8	15.0	11.0	30.7	31.2
Godrej Agrovet	Buy	750	940	25	18.7	26.3	34.5	44.1	40.3	31.3	28.6	21.7	5.1	4.4	18.9	21.7
Indian Hotels	Buy	709	770	9	8.9	11.2	14.4	25.9	26.8	28.0	63.1	49.3	9.2	7.8	15.7	17.2
Indiamart Inter.	Buy	3011	3700	23	55.2	70.2	84.1	19.0	27.3	19.8	42.9	35.8	8.7	7.4	22.1	22.2
Info Edge	Neutral	8339	7400	-11	64.3	76.6	93.4	102.2	19.1	22.0	108.9	89.3	4.1	3.9	3.8	4.5
Interglobe	Neutral	4690	4655	-1	211.8	193.8	209.1	2,678.8	-9	8	24.2	22	19.2	10.3	131.9	
Kajaria Ceramics	Buy	1410	1750	24	27.2	30.7	38.0	27.2	13.0	23.6	45.9	37.1	7.8	7.0	17.4	19.5
Lemon Tree Hotel	Buy	126	165	31	1.9	2.4	3.8	25.7	26.5	59.1	52.5	33.0	8.5	6.8	17.7	22.9
MTAR Tech	Buy	1807	2100	16	18.2	29.7	52.1	-45.7	62.7	75.4	60.9	34.7	7.2	6.0	12.6	18.9
IVITAN ICUII	Duy	1007	2100	10	10.2	23.1	J2.1	+3.7	02.7	75.4	00.5	54.7	1.2	0.0	12.0	10.5







		CMP	TP	% Upside		EPS (INR)	EPS	Gr. YoY	(%)	P/I	E (x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside	FY24	FY25E	FY26E	FY24	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
One 97	Neutral	724	650	-10	-22.4	-28.6	-12.1	-20.2	Loss	Loss	NM	NM	3.8	4.0	-14.4	-6.6
Quess Corp	Neutral	729	770	6	20.4	28.4	35.1	78.3	38.9	23.9	25.7	20.7	2.8	2.6	14.8	17.0
SIS	Buy	401	530	32	13.0	29.1	36.4	-44.2	124.7	24.9	13.8	11.0	1.0	0.8	16.7	17.3
Team Lease Serv.	Buy	3008	4000	33	64.8	83.0	127.1	-0.5	28.1	53.1	36.2	23.7	5.5	4.5	14.8	19.1
UPL	Neutral	583	650	12	3.7	26.3	45.1	-93.7	618.2	71.8	22.2	12.9	1.2	1.1	8.0	12.9
Updater Services	Buy	383	490	28	11.4	16.0	22.4	67.8	41.2	39.7	23.9	17.1	2.6	2.3	11.8	14.3
Zomato	Buy	278	320	15	0.4	1.0	3.3	-134.9	149.5	219.9	272.8	85.3	11.2	9.9	4.2	12.3





Index and MOFSL Universe stock performance

Index	1 Day (%)	1M (%)	12M (%)
Sensex	-0.3	-0.2	22.4
Nifty-50	-0.1	0.2	26.0
Nifty Next 50	0.1	1.4	66.6
Nifty 100	-0.1	0.3	32.0
Nifty 200	0.0	0.3	34.1
Company	1 Day (%)	1M (%)	12M (%)
Automobiles	-0.3	4.7	63.4
Amara Raja Ener.	0.5	0.5	119.1
Apollo Tyres	-0.2	-3.6	33.6
Ashok Leyland	1.0	-5.7	29.2
Bajaj Auto	0.4	4.0	134.5
Balkrishna Inds	-1.2	-1.3	16.9
Bharat Forge	-0.6	-4.4	33.9
Bosch	0.5	15.6	94.9
CEAT	0.9	5.4	40.1
Craftsman Auto	0.2	4.7	38.4
Eicher Motors	0.6	0.0	35.6
Endurance Tech.	0.6	-4.3	47.4
Escorts Kubota	-0.9	4.7	15.8
Exide Inds.	3.6	12.3	101.7
Happy Forgings	-0.9	-6.2	
Hero Motocorp	0.4	-3.2	76.6
M & M	-1.9	18.1	101.4
CIE Automotive	-0.7	-2.2	17.2
Maruti Suzuki	-1.3	4.4	22.7
MRF	0.0	-2.3	22.7
Sona BLW Precis.	-0.8	-8.3	18.8
Motherson Sumi	1.3	15.8	123.1
Motherson Wiring	-0.1	-5.4	5.1
Tata Motors	0.2	-4.7	46.8
TVS Motor Co.	0.0	1.3	80.3
Tube Investments	2.4	7.8	44.5
Banks-Private	-0.5	0.2	10.9
AU Small Fin. Bank	-1.4	-4.4	-3.5
Axis Bank	-1.0	-1.2	15.0
Bandhan Bank	12.0	7.4	-15.5
DCB Bank	-0.3	-2.2	-3.7
Equitas Sma. Fin	-0.2	-2.6	103.4
Federal Bank	1.0	2.4	27.6
HDFC Bank	-0.7	0.4	7.2
ICICI Bank	-1.6	-1.1	28.3
IDFC First Bank	-1.1	1.2	-21.0
IndusInd Bank	-0.6	-5.2	-5.2
Kotak Mah. Bank	0.3	5.2	6.3
RBL Bank	1.8	-2.5	-16.9
SBI Cards	-0.5	-2.5 -7.9	-8.4
Banks-PSU	0.0	1.3	28.9
BOB	-1.5	4.1	17.0
Canara Bank	-0.1	2.3	40.7
Indian Bank	0.1	2.9	24.0
Punjab Natl.Bank	1.2	-2.4	37.9
St Bk of India	0.3	4.1	35.9
Union Bank (I)	0.1	-2.9	9.6
Omon bank (I)	0.1	-2.3	5.0

Index	1 Day (%)	1M (%)	12M (%)
Nifty 500	0.1	0.3	35.6
Nifty Midcap 100	0.5	0.5	46.3
Nifty Smallcap 100	0.6	-0.8	47.7
Nifty Midcap 150	0.4	0.8	45.3
Nifty Smallcap 250	0.5	-0.1	47.6
NBFCs	-0.6	0.1	18.5
Aditya Birla Capital Ltd	-1.6	3.3	23.5
Angel One	3.7	12.8	28.6
Bajaj Fin.	-0.2	-0.6	-9.9
BSE	6.6	56.0	203.5
Cholaman.Inv.&Fn	-1.1	-1.3	19.2
Can Fin Homes	1.1	0.3	14.9
Cams Services	0.2	2.9	86.3
CreditAcc. Gram.	-3.9	-11.2	-21.7
Fusion Microfin.	0.3	-26.8	-63.0
Five-Star Bus.Fi	-0.1	8.6	7.9
Home First Finan	-2.0	9.7	42.4
Indostar Capital	-0.6	-3.4	53.3
IIFL Finance	3.3	0.4	-22.7
L&T Finance	-2.2	-1.5	23.3
LIC Housing Fin.	0.6	-8.4	30.7
MCX	3.5	21.0	197.3
M & M Fin. Serv.	-0.1	-11.9	-2.2
Muthoot Finance	0.1	-0.2	57.4
Manappuram Fin.	-1.4	-7.6	28.2
MAS Financial Serv.	1.4	5.1	-2.9
360 One	3.3	-2.4	104.7
PNB Housing	2.5	-12.1	34.3
Power Fin.Corpn.	-0.9	-6.7	87.1
REC Ltd	-1.2	-4.4	84.5
Repco Home Fin	-0.7	-8.8	28.1
Shriram Finance	0.1	1.9	76.0
Spandana Sphoort	-3.0	-11.4	-34.5
Insurance			
HDFC Life Insur.	0.0	3.4	16.5
ICICI Pru Life	-0.4	-1.1	41.5
ICICI Lombard	-0.6	-2.9	57.4
Life Insurance	-1.7	-6.4	48.9
Max Financial	0.2	3.7	30.3
SBI Life Insuran	0.0	-6.7	32.5
Star Health Insu	-3.3	-11.8	-5.2
Chemicals			
Alkyl Amines	-1.0	0.1	-0.4
Atul	-1.0	0.3	14.4
Clean Science	0.4	0.2	12.7
Deepak Nitrite	2.1	-3.1	35.1
Fine Organic	-1.2	-4.0	3.6
Galaxy Surfact.	-1.9	-6.0	10.6
Navin Fluo.Intl.	-0.1	2.5	-8.6
NOCIL	0.2	0.4	28.6
P I Inds.	-0.8	-2.1	29.8
SRF	0.3	-5.4	4.4
Tata Chemicals	2.8	14.8	14.2





Index and MOFSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Vinati Organics	0.4	2.4	7.9
Capital Goods	2.7	-7.0	-3.7
A B B	0.5	13.0	104.4
Bharat Electron	-0.3	-0.7	107.5
Cummins India	-0.5 -4.5	-4.8	106.3
Hitachi Energy	-0.4	30.7	286.2
K E C Intl.	-1.8	4.8	52.9
Kalpataru Proj.	-0.2	-2.6	103.4
Kirloskar Oil	1.1	-8.5	116.3
Larsen & Toubro	0.7	-0.5	12.8
Siemens	0.8	17.6	117.8
Thermax	1.9	15.3	74.3
Triveni Turbine	6.9	5.6	106.8
Zen Technologies	-1.9	17.8	157.0
Cement	-1.9	17.0	137.0
Ambuja Cem.	0.0	-6.1	31.5
ACC	0.0	-5.3	13.4
Birla Corp.	-1.3	-5.5 -8.7	-5.0
Dalmia Bhar.	1.3	-0.7	-18.6
Grasim Inds.	0.0	1.5	38.0
India Cem	0.0	-0.2	58.4
J K Cements	-0.4	-0.2 -7.8	33.0
JK Lakshmi Cem.	1.5	5.1	22.3
The Ramco Cement	-0.1	2.9	-12.4
Shree Cement	-0.1	-5.0	-8.2
UltraTech Cem.	-0.1	-0.6	36.9
Consumer	0.0	-0.0 - 4.2	18.8
Asian Paints	-0.7	-9.8	-4.0
Britannia Inds.	-0.4	-0.5	31.3
Colgate-Palm.	1.3	1.0	79.0
Dabur India	-0.1	-14.0	5.0
Emami	-1.7	-10.3	40.5
Godrej Consumer	-0.1	-10.3	33.5
Hind. Unilever	1.0	-4.2	8.9
ITC	-0.8	- 4.2 -5.1	8.9
Indigo Paints	0.9	-5.1	2.5
Jyothy Lab.	-1.4	-1.1 -9.0	43.0
Marico	0.1	0.7	27.9
Nestle India	0.0	-0.6	8.3
Page Industries	2.7	8.5	14.8
Pidilite Inds.	-0.9	-4.4	25.0
P & G Hygiene	-0.8	0.7	-6.5
Tata Consumer	-0.1	-7.6	26.9
United Breweries	0.1	0.2	32.0
United Spirits	0.8	-0.2	44.7
Varun Beverages	0.6	-5.6	61.4
Consumer Durables	0.5	0.8	42.0
Polycab India	-0.1	9.3	42.4
R R Kabel	-0.4	0.4	17.8
Havells	0.0	-1.0	39.4
Voltas	0.7	-2.1	107.4
KEI Industries	1.0	4.5	71.4
	1.0	1.5	, 1.7

EMS Amber Enterp. -1.9 13.6 73.5 Avalon Tech 1.1 19.4 13.2 Cyjent DIM -1.0 -1.2 3.2 Data Pattern -0.9 -8.2 18.4 Dixon Technolog. 1.4 19.0 188.2 Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Alembic Pharma -1.6 -6.1 44.6 Alkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2	Company	1 Day (%)	1M (%)	12M (%)
Avalon Tech 1.1 19.4 13.2 Cyient DLM -1.0 -1.2 3.2 Data Pattern -0.9 -8.2 18.4 Dixon Technolog. 1.4 19.0 188.2 Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Allembic Pharma -1.6 -6.1 44.6 Allem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8	EMS			
Cyient DLM -1.0 -1.2 3.2 Data Pattern -0.9 -8.2 18.4 Dixon Technolog. 1.4 19.0 188.2 Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Alembic Pharma -1.6 -6.1 44.6 Alkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0	Amber Enterp.	-1.9	13.6	73.5
Data Pattern -0.9 -8.2 18.4 Dixon Technolog. 1.4 19.0 188.2 Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Alembic Pharma -1.6 -6.1 44.6 Alkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glemark 1.7 3.8 129.4 </td <td>Avalon Tech</td> <td>1.1</td> <td>19.4</td> <td>13.2</td>	Avalon Tech	1.1	19.4	13.2
Dixon Technolog. 1.4 19.0 188.2 Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Allembic Pharma -1.6 -6.1 44.6 Allembic Pharma -1.2 37.1 74.8 Apollo Hospitals 0.4 1.2 37.1 90.5 Aurobindo 2.0 -0.8 66.2 28.1 Biocon 0.1 -10.2 34.5 22.0 36.2 20.2 34.5 22.0 36.2 20.2 18.5 22.0 20.2 18.5 28.8 18.5 29.4 30.8 29.4 30.2 <th< td=""><td>Cyient DLM</td><td>-1.0</td><td>-1.2</td><td>3.2</td></th<>	Cyient DLM	-1.0	-1.2	3.2
Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Allembic Pharma -1.6 -6.1 44.6 Allkem Lab 0.8 -1.4 74.8 Appollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0	Data Pattern	-0.9	-8.2	18.4
Kaynes Tech 0.9 19.9 108.9 Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Alembic Pharma -1.6 -6.1 44.6 Allem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0	Dixon Technolog.	1.4	19.0	188.2
Syrma SGS Tech. 1.0 -0.7 -33.6 Healthcare 1.2 1.6 55.4 Alembic Pharma -1.6 -6.1 44.6 Allkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -0.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5		0.9	19.9	108.9
Alembic Pharma -1.6 -6.1 44.6 Alkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4	Syrma SGS Tech.	1.0	-0.7	-33.6
Alkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glemark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8	Healthcare	1.2	1.6	55.4
Alkem Lab 0.8 -1.4 74.8 Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glemark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8	Alembic Pharma	-1.6	-6.1	44.6
Apollo Hospitals 0.4 1.2 37.1 Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3	Alkem Lab		-1.4	74.8
Ajanta Pharma -0.4 -1.7 90.5 Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Markind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7				
Aurobindo 2.0 -0.8 66.2 Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 0.8 3.0 68.5 Torrent Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 KNR Construct1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 -1.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Vetals -1.0 -6.4 -1.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4	_ 			
Biocon 0.1 -10.2 34.5 Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5				
Zydus Lifesci. 0.7 -4.3 77.4 Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5				
Cipla -1.4 -2.0 36.2 Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 1.4 -6.0 124.6 Sun Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8				
Divis Lab 3.4 12.9 63.8 Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6				
Dr Reddy's 0.2 -0.2 18.5 ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8	- 			
ERIS Lifescience -0.7 -4.6 54.8 Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 <td></td> <td></td> <td></td> <td></td>				
Gland Pharma -0.2 -10.0 4.0 Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.2 3.4 26.2 </td <td></td> <td></td> <td></td> <td></td>				
Glenmark 1.7 3.8 129.4 Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.2 3.4 26.2 Container Exp. -1.2 3.4 26.2 <				
Global Health -1.3 -8.3 33.7 Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 0.8 3.0 68.5 Torrent Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Granules 4.4 -10.8 71.0 GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2				
GSK Pharma 0.8 -2.7 81.5 IPCA Labs 4.1 15.2 75.7 Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics 1.5 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 </td <td></td> <td></td> <td></td> <td></td>				
PCA Labs				
Laurus Labs 1.9 -6.4 18.4 Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 <td></td> <td></td> <td></td> <td></td>				
Lupin 3.2 0.7 91.8 Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 <td></td> <td></td> <td></td> <td></td>				
Mankind Pharma 4.0 14.8 57.3 Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Max Healthcare -1.3 7.2 63.7 Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.0 -6.4 13.4 Logistics -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 <td></td> <td></td> <td></td> <td></td>				
Piramal Pharma 1.4 -6.0 124.6 Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.0 -6.4 13.4 Logistics -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 <				
Sun Pharma 0.8 3.0 68.5 Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 </td <td></td> <td></td> <td></td> <td></td>				
Torrent Pharma 1.6 1.8 85.5 Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics -1.0 -6.4 13.4 Logistics -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9				
Infrastructure 0.1 0.2 45.8 G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics				
G R Infraproject -1.8 -0.3 33.6 IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
IRB Infra.Devl. 1.4 -0.7 83.8 KNR Construct. -1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
KNR Construct. -1.0 -6.4 13.4 Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Logistics Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Adani Ports -0.6 -1.6 72.8 Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4		-1.0	-6.4	13.4
Blue Dart Exp. -1.2 3.4 26.2 Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Container Corpn. 0.7 -4.6 28.0 JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
JSW Infrast 1.6 -2.9 86.0 Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Mahindra Logis. 1.5 6.8 43.1 Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Transport Corp. 1.0 -4.9 32.8 TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
TCI Express -0.1 -8.5 -25.2 VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
VRL Logistics 1.8 -5.3 -12.6 Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Media 0.6 0.1 -8.8 PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
PVR INOX 0.8 2.3 -4.5 Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Sun TV -0.9 -3.0 25.9 Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Zee Ent. 0.6 -3.9 -49.9 Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Metals 0.9 10.0 45.8 Hindalco 2.4 15.4 54.4				
Hindalco 2.4 15.4 54.4			-3.9	
	Metals	0.9	10.0	45.8
Hind. Zinc -0.9 5.8 58.9	Hindalco	2.4	15.4	54.4
	Hind. Zinc	-0.9	5.8	58.9





Index and MOFSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
JSPL	1.5	4.0	45.2
JSW Steel	0.5	9.1	30.2
Nalco	4.8	30.0	132.7
NMDC	3.2	13.0	55.5
SAIL	3.1	5.6	51.3
Tata Steel	0.6	8.4	28.6
Vedanta	1.0	16.8	118.5
Oil & Gas	0.6	-0.7	61.2
Aegis Logistics	-1.6	-19.9	110.7
BPCL	0.7	-0.8	97.1
Castrol India	-0.2	-11.0	64.5
GAIL	1.7	5.6	85.7
Gujarat Gas	-0.5	-6.9	42.3
Gujarat St. Pet.	0.3	-4.4	43.2
HPCL	0.8	-3.4	133.5
IOCL	-0.8	-3.9	81.9
IGL	-0.1	2.4	17.4
Mahanagar Gas	-1.9	1.4	64.9
MRPL	-0.6	-6.6	78.1
Oil India	2.1	0.5	181.2
ONGC	1.3	2.5	59.6
PLNG	0.9	5.9	58.0
Reliance Ind.	0.1	-5.5	17.0
Real Estate	-0.7	1.4	70.2
Brigade Enterpr.	-0.7	-1.9	111.8
DLF	-1.6	2.7	49.8
Godrej Propert.	0.0	6.4	74.5
Kolte Patil Dev.	1.0	-2.4	-22.8
Mahindra Life.	2.7	-7.0	-3.7
Macrotech Devel.	-1.2	-2.3	43.7
Oberoi Realty Ltd	2.1	9.6	67.1
SignatureGlobal	-0.8	2.2	197.9
Sobha	0.4	-3.6	132.3
Sunteck Realty	-1.3	-1.0	18.2
Phoenix Mills	-2.3	-5.3	69.3
Prestige Estates	-0.4	3.6	156.2
Retail			
Aditya Bir. Fas.	0.8	7.2	53.2
Avenue Super.	-0.8	-13.7	18.7
Bata India	0.8	-0.8	-14.0
Campus Activewe.	0.3	5.1	10.6
Barbeque-Nation	2.2	10.4	-10.6
Devyani Intl.	1.1	-3.6	-15.6
Jubilant Food	0.9	-5.0	18.5
Kalyan Jewellers	0.2	9.7	165.6
Metro Brands	1.3	-2.3	5.2
Relaxo Footwear	-0.5	-4.5	-11.9
Restaurant Brand	0.3	1.8	-14.3
Sapphire Foods	3.8	10.7	29.4
Senco Gold	-2.1	14.2	113.6
Shoppers St.	-0.1	-13.2	15.5
Titan Co.	0.8	-13.2 -6.4	5.9
Trent	2.6	15.2	291.9
THETH	2.0	13.2	231.9

Company	1 Day (%)	1M (%)	12M (%)
V-Mart Retail	2.1	23.8	129.5
Vedant Fashions	1.8	4.0	1.9
Westlife Food	-2.1	10.8	-5.1
Technology	0.6	-0.3	30.1
Cyient	-0.5	-11.0	8.4
HCL Tech.	1.7	3.4	47.7
Infosys	0.8	1.3	29.5
LTIMindtree	1.0	1.8	22.2
L&T Technology	0.7	-7.8	10.1
Mphasis	0.8	-6.2	16.7
Coforge	1.4	7.9	43.2
Persistent Sys	4.4	3.4	89.9
TCS	-1.8	-7.4	14.9
Tech Mah	1.7	2.8	33.7
Wipro	0.6	2.7	25.4
Zensar Tech	1.0	-9.3	27.9
Telecom	0.2	-4.4	44.0
Bharti Airtel	0.6	6.9	76.6
Indus Towers	-0.1	-11.6	96.3
Idea Cellular	-1.4	-30.1	-22.5
Tata Comm	0.6	-1.0	7.1
Utiltites	-0.4	4.3	85.9
Coal India	1.0	1.9	63.3
NTPC	0.0	8.4	77.0
Power Grid Corpn	-1.3	-0.9	66.3
Tata Power Co.	-1.0	5.9	81.6
JSW Energy	-3.0	-4.7	77.9
Indian Energy Ex	1.1	-3.4	53.6
Others			
APL Apollo Tubes	-0.1	10.0	-5.8
Cello World	-0.7	-2.1	
Coromandel Intl	0.7	-3.5	42.7
Dreamfolks Servi	-0.7	-8.8	28.1
EPL Ltd	-2.6	4.8	36.1
Gravita India	1.0	11.0	175.2
Godrej Agrovet	-1.4	-3.1	52.0
Havells	0.0	-1.0	39.4
Indian Hotels	0.3	3.5	70.8
Indiamart Inter.	-0.6	-2.9	57.4
Info Edge	-1.7	-6.4	48.9
Interglobe	0.6	-4.2	85.3
Kajaria Ceramics	1.3	-1.6	9.4
Lemon Tree Hotel	0.9	-3.0	6.2
MTAR Technologie	0.3	1.8	-29.0
One 97	-1.0	8.7	-25.4
Piramal Enterp.	2.6	3.5	1.1
Quess Corp	-0.1	-7.8	70.6
SIS	-1.0	-1.2	-10.6
Team Lease Serv.	-1.9	-4.0	16.1
UPL	-0.2	-4.6	-7.1
Updater Services	0.5	3.4	31.9
Voltas	0.7	-2.1	107.4
Zomato Ltd	0.8	2.1	154.6
			-

Investment in securities market are subject to market risks. Read all the related documents carefully before investing



NOTES



Explanation of Investment Rating	Explanation of Investment Rating				
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	< - 10%				
NEUTRAL	> - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.moti

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) d)
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement Companies where there is interest Analyst ownership of the stock Nο

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com_Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under

14 October 2024 31



applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motifal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID				
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com				
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com				
Mr. Ajay Menon	022 40548083	am@motilaloswal.com				

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.